NATURE INSPIRED BROMOTYROSINE OXIME DERIVATIVES AS ANTI-ALGAE AGENTS AND SMALL MOLECULE INHIBITORS OF THE CHIKUNGUNYA VIRUS by CUI YAN TING
 
 
NATURE INSPIRED BROMOTYROSINE OXIME DERIVATIVES 
AS ANTI-ALGAE AGENTS AND SMALL MOLECULE 
INHIBITORS OF THE CHIKUNGUNYA VIRUS 
 
CUI YAN TING 
(B.Sc. (Hons.), NTU) 
 
 
A THESIS SUBMITTED  
 
FOR THE DEGREE OF MASTER OF SCIENCE 
 
DEPARTMENT OF PHARMACY 
 








 First of all, I am especially grateful to my supervisor, Assoc. Prof. Christina Chai, for 
her constant guidance, advice and support throughout my studies. Without her 
encouragement, I would not have undertaken a part-time master degree program in the first 
place.  
 I would also like to thank Dr. Lisa Ng and Dr.  Jason Kam from the Singapore 
Immunology Network (SIgN), A*STAR, for their help on the biological testing of target 
compounds and guidance on matters regarding the chikungunya virus. 
 I also owe a great deal of gratitude to a number of professors at the department and 
university. Those especially deserving of a mention include Assoc. Prof. Go Mei Lin, Assist. 
Prof. Chew Eng Hui, Assist. Prof. Ang Wee Han and Dr. Serena Teo. They have all provided 
me with invaluable advice and I have learned a great deal from all of them. I sincerely thank 
them for their help, in one way or another.  
 I would also like to thank my friends and colleagues who have given me invaluable 
advice and support throughout. Those especially deserving of a mention include Dr. Ngai 
Mun Hong, Dr. Sridhar Santhanakrishnan, Ms. Tang Shi Qing, Mr. Ching Kuan Chieh, Ms. 
Yap Siew Qi, Ms. So Choon Leng, Ms. Gan Fei Fei, Mr. Chin Chee Fei, Mr. Wang Lei and 
Mr. Peng Shiyong. Other lab members have also been immensely supportive morally. 
  Special thanks also go to the support staff, Ms. Ng Sek Eng, Mdm. Oh Tang Booy and 
Mr. Johannes Murti Jaya for their assistance. Lastly, I would like to thank the Ministry of 
Education (MOE), Singapore for funding my graduate research studies at the National 
University of Singapore (NUS), Department of Pharmacy








List of Tables ............................................................................................................................. 9 
List of Figures .......................................................................................................................... 10 
List of Schemes ........................................................................................................................ 12 
List of Graphs .......................................................................................................................... 13 
1  Introduction ...................................................................................................................... 14 
1.1  Introduction to marine natural products in drug discovery ...................................... 14 
1.2  Bromotyrosine-derived secondary metabolites from marine sponges ..................... 14 
1.3  Bromotyrosine-oximes and Psammaplin A ............................................................. 16 
1.4  Aim of the project .................................................................................................... 17 
2  Synthesis ........................................................................................................................... 20 
2.1  Design of compound library .................................................................................... 20 
2.2  Retrosynthesis of target compounds ........................................................................ 21 
2.3  Synthesis of precursors ............................................................................................ 22 
2.3.1  Synthesis of para-methoxybenzyl (PMB) hydroxylamine ................................ 22 
2.3.2  Synthesis of 3-bromo-4-methoxy and 3,5-dibromo-4-methoxybenzaldehyde .. 23 
2.4  Synthesis of target compounds ................................................................................ 25 
3  Antifouling........................................................................................................................ 33 
Table of Contents 
5 
 
3.1  Introduction to biofouling and tributyl tin (TBT) .................................................... 33 
3.2  Hypothesis and objective ......................................................................................... 34 
3.3  Biology ..................................................................................................................... 34 
3.3.1  Amphora adhesion assay- single concentration ................................................. 35 
3.3.2  Amphora adhesion assay- dose-response ........................................................... 35 
3.4  Results and discussion ............................................................................................. 36 
3.4.1  Single concentration assay ................................................................................. 36 
3.4.2  Dose-response assay .......................................................................................... 37 
3.4.3  Investigating the physical properties that govern solubility .............................. 38 
3.4.4  Determining the highest DMSO concentration Amphora can tolerate .............. 39 
3.5  Conclusion ............................................................................................................... 40 
3.6  Future work .............................................................................................................. 41 
4  Chikungunya virus (CHIKV) ........................................................................................... 42 
4.1  Introduction to chikungunya virus (CHIKV) ........................................................... 42 
4.2  CHIKV infection and clinical symptoms ................................................................. 43 
4.2.1  Acute stage ......................................................................................................... 43 
4.2.2  Chronic stage ..................................................................................................... 44 
4.3  Challenges and opportunities in the discovery of novel anti-CHIKV drugs ........... 45 
4.4  Hypothesis and objective ......................................................................................... 45 
4.5  Biology ..................................................................................................................... 46 
4.5.1  Cell viability assay ............................................................................................. 46 
4.5.2  Anti-CHIKV assay ............................................................................................. 47 
4.6  Results and discussion ............................................................................................. 48 
4.6.1  Anti-viral activity against the CHIKV ............................................................... 48 
4.6.2  Toxicity .............................................................................................................. 55 
4.7  Second generation compounds ................................................................................ 60 
Table of Contents 
6 
 
4.8  Synthesis of second generation compounds ............................................................ 61 
4.9  Second generation compounds – anti-viral activity ................................................. 62 
4.9.1  The combined effect of the 3-bromo-4-methoxy groups ................................... 62 
4.9.2  The effect of amide substituent .......................................................................... 63 
4.9.3  The effect of aromatic ring B ............................................................................. 64 
4.9.4  The role of free oxime on anti-viral activity ...................................................... 65 
4.9.5  Correlation of lipophilicity and anti-viral activity ............................................. 65 
4.10  Second generation compounds – toxicity ................................................................ 66 
4.10.1  Effect of the 3-chloro and O-methyl substituted oxime ..................................... 66 
4.10.2  Correlation of lipophilicity and toxicity ............................................................ 67 
4.11  Conclusion ............................................................................................................... 68 
4.12  Future work .............................................................................................................. 69 
References ................................................................................................................................ 71 
Appendix I - Experimental ....................................................................................................... 76 
Chemistry: Materials and Methods ...................................................................................... 76 
General procedure for the synthesis of azlactone ................................................................. 77 
General procedure for the hydrolysis of azlactone to arylpyruvic acid ............................... 79 
General procedure for the synthesis of PMB oxime acid ..................................................... 80 
General procedure for amide bond formation ...................................................................... 83 
General Procedure for OPMB de-protection ........................................................................ 96 
Biology: Materials and Methods ........................................................................................ 108 
Amphora coffeaeformis ...................................................................................................... 108 
Amphora adhesion assay – single concentration ................................................................ 108 
Amphora adhesion assay – dose-response ......................................................................... 109 
Table of Contents 
7 
 
HEK293T cells and CHIKV .............................................................................................. 109 
HEK293T cell viability assay ............................................................................................ 109 
Antiviral assay (CHIKV-Gluc assay) ................................................................................. 110 
Data analysis ...................................................................................................................... 111 
Compound libraries and reference compounds .................................................................. 111 
Appendix II ............................................................................................................................ 112 
NMR Spectra ...................................................................................................................... 112 
HPLC Spectra ..................................................................................................................... 166 
Appendix III ........................................................................................................................... 184 






 Synthetic compound libraries of derivatives of the bromotyrosine-oxime alkaloids 
isolated from marine sponges were tested for anti-algae activities against the diatom, 
Amphora coffeaeformis and anti-viral activities against the chikungunya virus (CHIKV).  
 In the anti-algae study, a single concentration cell adhesion assay was first used to 
screen for potential compounds, followed by a dose-response adhesion assay to determine the 
EC50 values (concentration that result in 50% decrease in number of attached cells) of the 
selected compounds. However, the Amphora adhesion assay was hampered by the poor 
solubility of the compounds in 30% salinity seawater. Attempt to improve the solubility by 
using a higher concentration of dimethylsulfoxide (DMSO) to dissolve the compounds was to 
no avail as DMSO was toxic to the cells. Analysis of the physical properties of the 
compounds suggests that the compounds should have cLogP values smaller than 3 and 
molecular weights less than 300 for them to be soluble, and future design of potential anti-
algae compounds should abide by this criteria.  
 In the CHIKV study, the toxicities and anti-viral activities of the compounds were 
tested by in vitro cell viability and anti-viral assays against the human embryonic kidney 
(HEK293T) cell-line. Several structural features that are important for a potent anti-viral and 
non-toxic compound were identified. Structural-activity relationship (SAR) studies and 
optimization of the lead compound resulted in compound 62 (EC50 4.3 µM, CC50 >1000 µM), 
which is the most active and non-toxic compound so far. 
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1 Introduction  
1.1 Introduction to marine natural products in drug discovery 
 Natural products have long been a source of inspiration in the drug discovery and 
development process. Before high-throughput screening of synthetic compound libraries was 
available, natural products and their derivatives made up ca. 80% of the approved drugs. 
Even to date, natural products continue to be a source of inspiration for new drugs as they are 
more likely to possess unique scaffolds and there is great potential for the development of 
new chemical entities as drugs.1 
 With 70% of Earth covered in oceans, it is estimated that biodiversity in the marine 
ecosystem is higher than that in the terrestrial ecosystem. Researchers have turned to marine 
natural products in their search for new drug candidates as it is believed that the oceans host 
an enormous number of novel chemical entities that may be useful towards the development 
of drugs with high efficacy, specificity and reduced toxicity. In 2004, ziconotide, a toxin 
isolated from the marine cone snail, is the first analgesic agent from a marine source to be 
approved by FDA. Owing to the success of ziconotide, the potential for marine-derived 
compounds to be developed as drugs has been recognised and this has paved the way for 
marine-derived compounds moving through clinical trials.2 
1.2 Bromotyrosine-derived secondary metabolites from marine sponges 
 Of the many marine organisms in the oceans, marine sponges are of particular interest 
as sources of secondary metabolites. Marine sponges are soft-bodied filter feeders found from 
intertidal shores to abyssal depths of more than 8500 m deep. They are sessile animals which 
have developed the ability to produce secondary metabolites as a mean of chemical defence 




scientists have found that many of these secondary metabolites possessed promising 
biological activity for the welfare of mankind.3 In this study, we were particularly interested 
in the class of secondary metabolite, bromotyrosine derivatives, first isolated in 1913 from 
two marine sponges, Verongia fistularis and Verongia cauliformis. Bromotyrosine-derived 
alkaloids have long shown to exhibit diverse biological activities such as anticancer, 
antifouling, antiviral, antimicrobial, ATPase regulator, calcium channel modulator etc. To 
date, more than 280 bromotyrosine alkaloids have been isolated and they can be broadly 
classified into 6 categories: simple bromotyrosine derivatives 1, 
spirocyclohexadienylisoxazolines 2, spirooxepinisoxazolines 3, oximes 4, bastadins 5, and 
other structural classes, for example alkaloid 6 (Figure 1). The simple bromotyrosine 
derivatives 1 are products that have undergone simple chemical transformations. In 
spirocyclohexadienylisoxazoline bromotyrosine derivatives 2, one or two bromotyrosine 
units are transformed into a spirocyclohexadienylisoxazoline. In the spirooxepinisoxazoline 
bromotyrosine derivatives 3, the bromotyrosine unit is expanded into a 
spirooxepinisoxazoline. The bromotyrosine oximes 4 have the amine functionality replaced 
by an oxime and the bastadins 5 are made up of four bromotyrosines by the oxidative 
phenolic coupling of two tyramine–tyrosine units connected through an amide bond. Alkaloid 








1 3 5 
   
2 4 6 
Figure 1. Six structural classes of bromotyrosine alkaloids 
 
1.3 Bromotyrosine-oximes and Psammaplin A 
 Among the six structural classes of bromotyrosine-derived alkaloids, we are 
particularly interested in the bromotyrosine-oximes 4 owing to their diverse in biological 
activities and simple yet highly modifiable structures. Some examples of biologically active 
brotyrosine-oximes 4 are shown in Figure 2.  
 The oxime-histamine, Ianthellin (7) isolated from the Bahamas sponge Ianthella ardis 
was found to be antibiotic and antifungal.5 It is also an antitumor agent and its mechanism of 
action includes inhibition of protein kinase activity and mitotic spindle formation.6 While 
verongamine (8) isolated from the sponge Verongula gigantean is a specific histamine-H3 
antagonist at a low concentration of 1 µg/mL,7 5-bromoverongamine (9) isolated from the 
sponge Pseudoceratina sp., collected in the Caribbean is antifouling by inhibiting barnacle 




 The oxime-disulfide, Psammaplin A (10) is known for possessing various 
bioactivities. It is a potent histone deacetylase and DNA methyltransferase inhibitor with low 
toxicity, as well as shows antiproliferative activities against many cancer cell lines such as 
A549 lung tumor and MDA-MB-435 breast tumor .9 Psammaplin A (10) was also reported to 
be antimicrobial against the Gram-positive bacteria; methicillin-resistant Staphylococcus 
auereus (MRSA) with inhibitory concentrations against 21 MRSA strains ranging from 0.781 
to 6.25 µg/mL.10 The antifouling activity of Psammaplin A (10) was shown by the inhibition 
of barnacle larvae settlement at 1 – 10 mM.11 Recently, it was also found to be antiviral by 
inhibiting the hepatitis C virus NS3 helicase and ATPase activities with IC50 values of 17 and 




Ianthellin (7) Verongamine (8) 
 
  
Bromoverongamine (9) Psammaplin A (10) 
  
Figure 2. Examples of biologically active bromotyrosine-oxime alkaloids 
 
1.4 Aim of the project 
 A search in the literature shows that studies on the structural activity relationship 
(SAR) of the most well studied bromotyrosine-oxime psammaplin A (10) and its derivatives 

































































































































synthesized and tested for the above mentioned biological activities. The biological results 
will be analyzed and SAR studies will aid in elucidating important structural features for the 





2.1 Design of compound library 
 In designing the library of compounds, the target compounds will retain the 
bromotyrosine backbone and oxime moiety of psammaplin A (10), while the disulfide moiety 
will be replaced with various amide functionalities. For convenience, the tyrosine-oxime 
aromatic ring is labelled as aromatic ring A, while aromatic ring B is the aromatic ring 
connected to the amide functionality. As shown in Table 1, four series of target compounds 
will be synthesised and each series differs by the substituents on aromatic ring A. Series 1 has 
an un-substituted aromatic ring A, series 2 is 4-methoxy substituted, series 3 has an additional 
bromine atom substituted at one of the ortho positions and series 4 is 3,5-dibromo-4-methoxy 
substituted. Derivatives for each series will be synthesised by amide bond formation reaction 
with benzylamine, phenethylamine, phenylpropylamine, and benzylamines that are 3-bromo-
4-methoxy or 3,5-dibromo-4-methoxy substituted. The compounds are designed to enable a 





Table 1. Target compound library 
Compound series 
(Aromatic ring A) 
R groups




11 12 13 
 
14 15  
Series 2 
 
21 17 18 
 
 19 20  
Series 3 
 
16 22 23 
 
24 25  
Series 4 
 
26 27 28 
 
29 30  
 
2.2 Retrosynthesis of target compounds 
 The formation of the target compounds will employ an amide bond formation reaction 
between the carboxylic acid precursors 32 and various amines as shown in Scheme 1. The 
carboxylic acid precursors 32 can be prepared via the condensation of para-methoxybenzyl 
(PMB) hydroxylamine (39) with arylpyruvic acids 33, which in turn, are obtained from acidic 
hydrolysis of azlactones 34. Azlactones 34 will then be synthesised under the reaction 




availability and diversity of benzaldehydes and amines provides a distinct advantage in the 
synthesis of a diverse synthetic library of compounds for testing. 
 
 
Scheme 1. Retrosynthesis of target compounds 
 
2.3 Synthesis of precursors 
Before proceeding to the synthesis of the target compounds, three precursors - para-
methoxybenzyl (PMB) hydroxylamine (39), 3-bromo-4-methoxybenzenaldehyde (35iii) and 
3,5-dibromo-4-methoxybenzaldehyde (35iv)  were prepared.  
 
2.3.1 Synthesis of para-methoxybenzyl (PMB) hydroxylamine 
A two step synthetic route was employed for the synthesis of PMB hydroxylamine 
(39) (Scheme 2). First, nucleophilic substitution of N-hydroxylphthalimide (36) with PMB 
chloride (37) in the presence of a base resulted in the formation of a phthalimide protected 




the presence of hydrazine to give the desired PMB hydroxylamine hydrochloride salt (39) in 
77% yield. 
 
Scheme 2. Synthesis of 39 
 
2.3.2 Synthesis of 3-bromo-4-methoxy and 3,5-dibromo-4-methoxybenzaldehyde 
 Multiple attempts were made to synthesize 3-bromo-4-methoxybenzaldehyde (35iii) 
and 3,5-dibromo-4-methoxybenzaldehyde (35iv). Our initial attempts to synthesise 
benzaldehyde 35iii utilised commercially available 4-methoxybenzaldehyde (35ii) with 1.0 
equivalent of liquid bromine and DCM as the solvent. However, no formation of product was 
observed when the reaction mixture was stirred at room temperature or refluxed for 12 hours 
(Table 2, entry 1 and 2). When acetic acid replaced DCM as the solvent, formation of 
benzaldehyde 35iii was observed. However, the reaction did not go to completion even after 
stirring at room temperature for 3 days, giving an inseparable mixture of both starting 
material 35ii and benzaldehyde 35iii (Table 2, entry 3).  
In order to increase the rate of this reaction, it was reasoned to use the more reactive 
4-hydroxybenzaldehyde (40) in the bromination step and then methylate it in the next step. 
To this end, 4-hydroxybenzaldehyde (40) was reacted with 1.0 equivalent of bromine and 




minutes, a mixture of starting material 40 and 3-bromo-4-hydroxybenzaldehyde (41) was 
obtained in a 4:10 ratio (Table 3, entry 1) 
However, the reaction did not proceed to completion. Prolonging the reaction time to 
45 minutes resulted in complete consumption of starting material 40 but mono- and 
di-brominated benzaldehydes, 41 and 42 were formed in a ratio of 10:6 (Table 3, entry 2). 
We were unable to monitor the reaction by thin-layer chromatography (TLC) as both the 
starting material 40 and the di-brominated benzaldehyde 42 was inseparated on the TLC plate. 
Therefore, the reaction was not optimized further and the crude mixture was used directly in 
the next step. The di-brominated benzaldehyde 42 was synthesized using 4-
hydroxylbenzaldehyde (40) and 2.0 equivalent of liquid bromine in acetic acid to give the 
desired benzaldehyde 42 in good yield (Table 3, entry 3). 
 
Table 2. List of bromination reaction conditions with 4-methoxybenzaldehyde (35ii) 
 
Entry Conditions Yield 
1 Br2 (1.0 eq.), DCM (1.0 M), rt, 12 h No reaction 
2 Br2 (1.0 eq.), DCM (1.0 M), reflux 40˚C, 12 h No reaction 
3 Br2 (1.0 eq.), AcOH (1.6 M), rt, 3 days 61%a 









Entry Conditions Yield 
1 Br2 (1.0 eq.), AcOH (1.6 M), rt, 30 min 
77%a 
 
2 Br2 (1.0 eq.), AcOH (1.6 M), rt, 45 min 
45% of 41 
29% of 42 
3 Br2 (2.0 eq.), AcOH (1.6 M), rt, 2 h 88 – 92% of 42 
ainseparable mixture of 40 and 41 (4 : 10) 
  
With benzaldehydes 41 and 42 in hand, methylation of the phenol with methyl iodide 
and potassium carbonate in DMF was carried out to give the desired products 35iii and 35iv 
in 80-90% yield (Scheme 3).  
 
Scheme 3. Methylation of phenol 
 
2.4 Synthesis of target compounds 
With all the required precursors in hand, the target compounds 11-30 were 
synthesized in 5 steps as shown Scheme 4.  Starting from benzaldehydes 35i-iv, the 
Erlenmeyer-Plöchl azlactone synthesis was employed to access azlactones 34i-iv in 67% to 
quantitative yield. Mechanistically, the carboxylic end of N-acetylglycine (43) reacts with 
acetic anhydride, resulting in compound 44 which has a better leaving group to promote its 
self-condensation to an oxazolone 45. Subsequently, condensation of benzaldehydes 35i-iv 





Scheme 4. Synthetic route to the target compounds (series 1 – 4) 
 
 





The synthesis of azlactone 34iv has been reported by Shearman et al.19 where they 
characterised azlactone 34iv as possessing the (Z)-stereochemistry using NMR spectroscopy 
and X-ray crystallography methods. Comparison of the reported chemical shift (6.90 ppm) of 
the H-7 proton to our synthesized product (6.92 ppm) suggests that the azlactone 34iv 
synthesized in our study was also the (Z)-isomer (Table 4). By analogy, the stereochemistry 
of azlactones 34i-iv synthesized in our work were also assumed to be the (Z)-isomer since 
only a single peak for the H-7 proton between 6.92 – 7.15 ppm was observed. 
 
Table 4. Proving and assigning the (Z)-stereochemistry of azlactones 34i-iv 





8.24 (2H, s, H-2 and H-6), 6.90 
(1H, s, H-7), 3.92 (3H, s, H-15), 
2.43 (3H, s, H-2’) 
8.26 (2H, s, H-2 and H-6), 6.92 
(1H, s, H-7), 3.94 (3H, s, H-15), 
2.43 (3H, s, H-2’) 
 
Shearman et al.19 reported a one-pot, two step saponification of azlactone 34iv with 
barium hydroxide octahydrate followed by condensation with PMBONH2·HCl (39) to give 
32iv in 54% yield (Scheme 6). However, in our hands, we were unable to reproduce the 
synthesis of 32iv and the major product obtained was the imine 46 (Scheme 7, route A).  
 
 





Scheme 7. Attempts to synthesize 32iv 
 
 In our attempt to investigate the mechanism of this reaction, we performed the 
reaction in a step-wise manner using the same conditions (Scheme 7, route B). In the first 
step, basic hydrolysis of azlactone 34iv with barium hydroxide octahydrate was carried out to 
give the intermediate 47 with a crude yield of 97%. Following that, intermediate 47 was 
treated with PMBONH2·HCl (39) at 60 ˚C for 6 hours. Analysis of the 1H NMR spectrum of 
the crude reaction mixture found imine 46 to be the major product, thus giving the same 
result as that observed with the one-pot reaction. Imine 46 is likely to arise from the 
1,4-michael addition of PMBONH2·HCl (39) to intermediate 47, followed by lactonisation 





Scheme 8. Proposed mechanism for the formation of imine 46 
 
In order to circumvent the formation of imine 46, azlactones 34i-iv were firstly 
hydrolysed under acidic conditions to yield arylpyruvic acids 33i-iv in 79% to quantitative 
yield. Under acidic hydrolysis conditions, intermediate 47 will not be formed, thus preventing 
the formation of imine 46. A representative example of the difference in mechanism between 





Scheme 9. Mechanism of the base and acid hydrolysis of azalactone 34iv. 
 
Arylpyruvic acids 33i–iv exist in their enol forms as only the vinyl proton (CH) peak 
was observed around 6.3 ppm in the 1H NMR spectra. No methylene proton (CH2) peak was 
observed (Figure 4). Condensation of arylpyruvic acids 33i-iv with PMBONH2·HCl (39) and 
sodium acetate in ethanol at room temperature gave the PMB protected oxime acids 32i-iv in 






Figure 4. Evidence for the enol form of arylpyruvic acids 33i-iv 
 
 
Scheme 10. Synthesis of 32i-iv from azlactones 34i-iv 
 
In the final 2 steps, para-methoxybenzyl (PMB) protected oxime amides 31i-iv were 
readily accessed from the acids 32i-iv and the corresponding amines using 
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC·HCl) as the coupling 
agent and 1-hydroxybenzotriazole hydrate (HOBt) as the additive in 22% - 95% yield. Lastly, 
removal of the PMB group with aluminium trichloride and anisole proceeded smoothly to 
furnish target compounds 11 – 30 in 30 - 81% yield.  
The mechanism for the removal of the PMB group is illustrated in Scheme 11. 
Aluminium trichloride acts as a Lewis acid and accepts a lone pair of electron from the 
oxygen atom of the protected oxime, forming a positive charge on oxygen. The positive 
charge is stabilised by donation of a pair of electrons from the cleavage of a neighbouring 
bond, resulting in 4-methoxybenzyl cation 48 . Anisole acts as a cation scavenger and 
undergoes an electrophilic aromatic substitution reaction with the cation to form the biphenyl 





Scheme 11. PMB deprotection mechanism 
 
X-ray crystallographic analysis of one of the target compounds, 14 confirmed that the 
oxime possessed the (E)-stereochemistry (Figure 5). Based on the crystal structure and 1H 
NMR data of 14, by analogy all other target compounds 11 – 30 were also assigned as 
possessing the (E)-stereochemistry. 
 
 






3.1 Introduction to biofouling and tributyl tin (TBT) 
 Biofouling, the unwanted growth of plants and animals on artificial submerged 
surfaces is a major problem for the shipping industry worldwide due to the reduction in boat 
speeds and increasing fuel consumption, resulting in enormous economical and environment 
losses.20 Biofouling includes macrofouling by macroalgae and invertebrates and microfouling 
by bacteria and diatom.21 The majority of existing anti-fouling management relies on toxic 
coatings on vessel hulls, commonly known as self-polishing antifouling paints to prevent 
settlement of marine organisms. The toxicants are incorporated into paints, released from the 
surface layers of the coatings and inhibit the settlement of marine organisms on ship hulls. In 
the 1960s, self-polishing antifouling paints containing tributyl tins (TBTs) were popularized 
and used worldwide due to the fact that TBT targets a wide range of organisms and has a 
modest cost of production and a durability of five years.22  However, TBT was found to cause 
severe toxicity on non-targeted fouling organisms leading to the ban in the of application of 
TBT on all vessels since 2001 and the use of TBT-free coatings since 2008 has been imposed 
by the International Maritime Organisation (IMO).9 The phenomenon of imposex where 
female sea snails exposed to TBT developed male organs is one indication of the non-target 
effects of TBTs. Furthermore, with large amounts of TBTs discharged into the oceans and 
their poor biodegradability, they can accumulate in marine organisms leading to chronic 
toxicity. For example, in fish the bioconcentration factors occur between 100–1000.23 Thus 
there is an urgent need to develop safer antifouling compounds and one strategy is to examine 




3.2 Hypothesis and objective 
As mentioned in section 1.3, secondary alkaloids bromoverongamine (9) and 
psammaplin A (10) isolated from marine sponges were shown to repel macrofoulers by 
inhibiting barnacle larvae settlement with EC50 values of 1.03 mg/mL and 1 – 10 mM 
respectively.8,11 Among the bromotyrosine alkaloids in the spirocyclohexadienyl isoxazolines 
category, hemifistularin-3 (50) also prevented the settlement of zebra mussel, Dreissena 
polymorpha, at 20.2 µg/mL.24 These alkaloids have in common a bromotyrosine backbone 
with an oxime moiety, from which our synthetic compound library was derived. Therefore, 
we hypothesize that our synthesized compounds will also exhibit antifouling properties. In 
this study, we will test the antifouling effects of our target compounds against microfoulers, 
in particular the diatom, Amphora coffeaeformis, which belongs to the class of microalgae. 
 
Figure 6. Hemifistularin-3 (50) 
 
3.3 Biology 
 To investigate the inhibitory activity of target compounds 11- 30 against Amphora 
coffeaeformis,an Amphpora adhesion assay was designed and conducted. In the first round of 
screening, a single concentration of the target compounds (12.5 µg/mL) was used. 
Compounds that did not prevent the settlement of the Amphora were eliminated while those 
that resulted in more than 40% decrease in attached cells as compared to dimethylsulfoxide 
(DMSO) were selected for further screening. In the second round of screening, selected 




response curves were plotted to calculate the EC50 values (concentration resulting in 50% 
decrease in attached cells) for each compounds.  
3.3.1 Amphora adhesion assay- single concentration 
 In the single concentration assay, 2000 Amphora suspended in 30% salinity seawater 
was added to each well of a 96-well plate, followed by the addition of target compounds 
11 - 30 at 12.5 µg/mL with 10 replicates per compound. The cells were incubated at 24 °C for 
24 hours with a 12 hours light, 12 hours dark cycle to simulate the natural growth condition. 
After 24 hours, any unattached Amphora were removed by aspirating the medium and 
washing the wells once with distilled water. The number of attached Amphora remaining was 
quantified by counting one field of view per well under the microscope. Compounds that 
resulted in more than 40% decrease in number of attached Amphora (compared to DMSO) 
were selected for the dose-response assay. 
3.3.2 Amphora adhesion assay- dose-response  
 In the dose response assay, 2000 Amphora suspended in 30% salinity seawater was 
added to each well of a 96-well plate, followed by the addition of selected compounds in a 
range of concentration from 2.5 – 160 µg/mL with 10 replicates per concentration. The cells 
were incubated at 24 °C for 24 hours with a 12 hours light, 12 hours dark cycle. After 24 
hours, any unattached Amphora were removed by aspirating the medium and washing the 
wells once with distilled water. The number of attached Amphora remaining was quantified 
by counting one field of view per well under the microscope with ultra-violet (UV) light. 
Under UV light, Amphora that are attached and viable appeared red and were quantified. On 
the other hand, Amphora that were not viable appeared yellow or green and they were 




compounds were determined by plotting the average number of attached Amphora against 
concentrations. 
3.4 Results and discussion 
3.4.1 Single concentration assay 
 At the compound concentration of 12.5 µg/mL, the percentage decrease in number of 
attached Amphora with respect to the negative control, DMSO ranged from 20 – 54%, with 
28 and 17 being the most and least effective respectively (Graph 1). Compounds that resulted 
in more than 40% decrease in number of attached cells are 13, 16 18, 22, 23, 24, 25 and 28 
(Figure 7). Analysis of the structures of these eight compounds suggests that derivatives with 
1) brominated ring A with a phenylpropylamide substituent and 2) brominated ring A and/or 
B with a benzylamide substituent were among the more effective inhibitors. However at this 
point, no trend on the SAR could be discerned. 
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Figure 7. Compounds that resulted in more than 40% decrease in number of attached Amphora, (%) indicates 
percentage decrease 
 
3.4.2 Dose-response assay 
The results from the dose-response assay are showed in Table 5. In the range of 
concentrations tested (2.5 – 160 µg/mL), six out of eight compounds (16, 18, 23– 25 and 28) 
were found to have precipitated from solution as observed by the needle-like crystal in the 
wells under the microscope. As there was no observable effect on the attachment of Amphora 
from the minimum concentration tested (2.5 µg/mL) to the concentration where precipitation 
occurred, we were unable to determine the EC50 values for these six compounds. Therefore, 
only the concentration at which they started to precipitate was reported. The EC50 values for 
the other two compounds, 13 and 22 in which precipitation did not occur were determined to 
be 72.3 and 18.0 µM respectively. Due to the lack of data, SAR of our target compounds with 





Table 5. EC50 values and physical properties of the 8 selected compounds 
Compound EC50 (µM) MW cLogP tPSA 
13 72.3 296.36 3.98 61.69 
16 >26.5 377.23 3.96 70.92 
18 >122.6 326.39 3.90 70.92 
22 18.0 391.26 4.29 70.92 
23 >49.3 405.29 4.67 70.92 
24 >53.1 486.15 4.65 80.15 
25 >51.4 565.05 5.33 80.15 
28 >51.6 484.18 5.35 70.92 
 
3.4.3 Investigating the physical properties that govern solubility 
Due to the fact that 30% salinity seawater was used as the culture medium in the dose-
response assay, the insolubility of the compounds in solution is not totally unexpected. To 
obtain a gauge on the physical properties of the compounds that would render their solubility 
in 30% salinity seawater, the molecular weight (MW), cLogP and total polar surface area 
(tPSA) for the eight compounds were calculated (Table 5).  It was noted that 22 which has the 
higher MW and cLogP values is soluble while 16 and 18 which have lower MW and cLogP 
values were insoluble. No absolute trend could be discerned from the MW and cLogP of the 
eight compounds with respect to solubility. Furthermore, the tPSA values for all eight 
compounds are similar suggesting that tPSA is not a factor that affects solubility. In general, 
we can only conclude that compounds with molecular weights larger than 405 and cLogP 





3.4.4 Determining the highest DMSO concentration Amphora can tolerate  
 The concentration of DMSO used in the dose-response assay is 1%. In our attempts to 
improve the solubility of our compounds, we considered the use of more DMSO to dissolve 
the compounds. However, the maximum concentration of DMSO that Amphora can tolerate 
will first need to be determined. In this assay, 2000 Amphora suspended in 100 µL of 30% 
salinity seawater were added to each well of a 96-well plate, followed by the addition of 100 
µL of 30% salinity seawater containing 1%, 2% and 3% DMSO. Wells that only contain 
Amphora suspended in 30% salinity seawater without DMSO were used as the negative 
control. The cells were then incubated at 24 °C for 24 hours with a 12 hours light, 12 hours 
dark cycle. After 24 hours, the wells were aspirated and washed once with distilled to remove 
any unattached cells. The number of attached cells remaining was quantified by counting 
under the microscope with ultra-violet (UV) light. The difference in number of attached cells 
with respect to the negative control was calculated and the result shown as the box-plot 
(Graph 2). From the box-plot, it is clear that DMSO concentration of more than 2% caused a 
significant decrease in number of attached Amphora with respect to the negative control. 
Therefore, we are unable to improve the solubility of the compounds for the assay as we 






Graph 2. Boxplot to show the toxic effect of DMSO on Amphora 
 
3.5 Conclusion 
 Unfortunately, in this study the poor solubility of the target compounds hampered the 
investigation of their effectiveness as anti-algae agents against the diatom Amphora 
coffeaeformis. An attempt to analyse the physical properties that governs solubility was to no 
avail as no discernable trend on the MW, cLogP and tPSA with respect to solubility could be 
established. We can only conclude that compounds with MW larger than 405 and cLogP 
values greater than 4.65 (see 23 - 25 and 28) should be avoided as they are likely to cause 
precipitation. In addition, we were unable to use a higher concentration of DMSO to improve 
the solubility of our compounds since DMSO was toxic to the cells at concentrations higher 
than 1%. Therefore, we were only able to successfully determine the EC50 values of 2 
compounds, 13 (EC50 72.3 µM) and 22 (EC50 18.0 µM). Due to the lack of data, we were 




3.6 Future work 
 More attention must be given to the design of future potential anti-algae compounds 
in view of the lack of solubility in seawater. From the results gathered, we proposed that the 
cLogP values and MW of the compounds should be less than 3 and 300, respectively for 
compounds to be soluble. An additional solubility test for the compounds should also be 





4 Chikungunya virus (CHIKV) 
4.1 Introduction to chikungunya virus (CHIKV) 
 Chikungunya virus (CHIKV) is an alphavirus belonging to the Togaviridae family of 
viruses and an arbovirus transmitted by Ades (Ae.) mosquitoes.25, 26 The virus, Chikungunya, 
meaning “that which bends up” was named owning to the sudden onset of extreme joint pains 
experienced by patients. The first case of CHIKV epidemic occurred on the Makonde Plateau 
in the Southern Province of Tanganyika, Africa in 1952.27 In Asia, the first major outbreak 
was dated back to Thailand in 1958,28, 29 and subsequent major outbreaks were documented in 
1960s - 1970s in India and South East Asia.30, 31 Recurrence of any major epidemic was 
absent for the next 30 years until recently, a large outbreak occurred in Kenya in 2004, first 
detected on Lamu island in July and 5 months later  on Comoros Islands. By the end of 
March 2005, islands in the entire Southwest Indian Ocean, including Mayotte, Reunion 
Island, Mauritius, Seychelles and Madagascar were infected by the CHIKV.32-34  More 
importantly, this outbreak sparked an epidemic that not only spread across the Indian Ocean, 
but also countries in South East Asia and Asia. Cases of CHIKV infection have been detected 
in almost 40 countries thus far (Figure 8).35 In Singapore, based on statistics given by the 
Ministry of Health, there was a major increase in the number of people infected by CHIKV in 






Figure 8. Worldwide distribution of the CHIKV35 
 
4.2 CHIKV infection and clinical symptoms 
4.2.1 Acute stage  
Acute infection lasts approximately 1 – 10 days after patients are bitten by infected 
mosquitoes. Those infected with CHIKV generally develop an abrupt onset of symptoms 
within 2 – 6 days. These symptoms are characterized by high fever (CHIKF), back pain, 
headache, polyarthralgia and fatigue.  Polyarthralgia, being the most characteristic is reported 
in 87-89% of the cases and could last beyond the acute stage by weeks to years.37, 38 Inflamed 
and swollen joints result in extreme joint pains and usually occur in the peripheral joints such 
as the wrists, ankles and phalanges and in some large joints such as the shoulders, elbows and 
knees. Other acute symptoms include cutaneous manifestations, illness related to the 
digestive system and psychological impact. The acute stage of CHIKF is characterized by a 
viral stage with high-titer viremia (on average 107 pfu/mL) during the first 4 days followed by 
a speedy decrease in viral load accompanied by a subside in fever and joint pains. Evident 
abnormalities related to CHIKF such as thrombocytopenia and lymphophenia and other less 
prominent abnormalities such as leucopenia, elevated creatine, elevated creatine kinase, 




convalescent stage (days 5 – 14), the CHIKV is almost non-detectable but improvement in 
clinical symptoms is slow.  
4.2.2 Chronic stage 
Following 1 -2 weeks after recovery from the acute stage, patients may experience a 
relapse of persistent symptoms such as joint pain, musculoskeletal pain and chronic 
rheumatic manifestations. In some cases, the pain can be extremely severe so much so that 
this results in increased disability in patients’ daily life such as the inability to walk and 
handle objects (Figure 9). Ultimately, a marked decreased in the quality of life and 
psychological health in patients is observed. Older patients (above 40 years old) who have 
existing rheumatic diseases are more susceptible to these persistent symptoms and increased 
duration of illness. In a cross-sectional study on the Reunion island outbreak, 53% of the 
patients suffer for more than 4 months after the onset of disease and in another outpatient 
cohort study, 20% of the patients did not recover from joint pain 300 days after the onset of 
disease.38, 40, 41 
 
 





4.3 Challenges and opportunities in the discovery of novel anti-CHIKV 
drugs 
CHIKV is a rapidly emerging arbovirus that is of global health concern. Due to the 
neglected status of CHIKV in the past, there is no effective drug or vaccine thus far. Patient 
management is largely targeted at symptomatic relief using anti-inflammatory drugs. While 
the best way to reduce viral transmission is to eliminate the breed of mosquitoes, developing 
chemotherapeutics targeting the virus in infected patients and vaccines to control the spread 
of infection remains an utmost priority. Efforts in medicinal chemistry focused on in silico 
and in vitro screening of synthetic chemical libraries, approved drugs in the market and 
natural products against the CHIKV, as the many strategies to discover lead compounds. 
4.4 Hypothesis and objective 
In a study conducted by Salam et al. in 2013, the bromotyrosine-oxime disulfide 
sponge alkaloid, psammaplin A (10) was found to inhibit the hepatitis C virus non-structural 
protein 3 (nsP3) helicase and ATPase activities with IC50 values of 17 and 32 µM 
respectively.12 The nsP3 protein which is also present in the CHIKV plays a central role in 
the replication and life-cycle of CHIKV. Therefore, we hypothesize that our synthesized 
target compounds, which are derivatives of psammaplin A (10) would be potential anti-
CHIKV compounds. In this study, the cytotoxicities and anti-CHIKV activities of our target 
(11 - 30) compounds would be tested against the human embryonic kidney (HEK293T) cell 
line. Information gathered from the structural-activity relationship (SAR) analysis would be 





4.5 Biology  
The target compounds were subjected to in vitro cell viability and anti-CHIKV assays 
against the HEK293T cells. Results from the cell viability assay provide information on 
cytotoxicity while results from the anti-viral assay provide information on the virus inhibitory 
strength. In a study conducted by Pohjala et al.,43 high-throughput screening of 356 natural 
products and clinical approved drugs on the CHIKV replicon cell line identified naringenin 
(51) as one of the 5,7-dihydroxyflavones that suppressed virus activity. Hence, naringenin 
(51) was used as a positive control in the biological assays conducted in this study.  
 
 
Figure 10. Naringenin (51) 
 
4.5.1 Cell viability assay 
 The in vitro cytotoxicities of the target compounds were tested against the HEK293T 
cells using the CellTiter-Glo® luminescent cell viability assay. In this assay, HEK293T cells 
were seeded on a 96 well plate for 24 hours followed by the addition of target compounds in 
a range of concentration from 0.01 µM to 1 mM. After an incubation time of 24 hours, the 
CellTiter-Glo® reagent was added and the cells were lysed. The lysis of metabolically active 
cells resulted in the generation of ATP, which is used to oxidize luciferin (52), by the enzyme 
luciferase, to produce oxyluciferin (53) and the release of energy in the form of luminescence. 
The intensity of luminescence is thus proportional to the number of viable cells. Therefore, 




(concentration that resulted in 50% cell death) for the target compounds can be determined 
(Figure 11, Scheme 12). 
 
 
Figure 11. Procedure for (a) the cell viability assay; (b) anti-CHIKV assay 
 
 
Scheme 12. Mono-oxygenation of 52 catalysed by luciferase in the presence of Mg2+, ATP and molecular oxygen 
 
4.5.2 Anti-CHIKV assay 
The in vitro anti-viral activities of target compounds were tested against the 




assay, HEK293T cells were seeded on a 96 well plate for 24 hours followed by infection with 
CHIKV tagged with the Gluc marker gene. After incubating for 90 minutes, the target 
compounds were added in a range of concentration from 0.01 µM to 1 mM and incubated for 
another 24 hours. At 24 hours post-infection, 50 µL of the cultured medium was transferred 
to a new 96 well plate and 50 µL of coelenterazine H (54) was added into the wells. In the 
presence of the enzyme luciferase (Gluc), coelenterazine H (54) undergoes an enzyme 
catalyzed oxidation to form coelenteramide (55) and the release of energy in the form of 
luminescence. The intensity of luminescence provides information on the number of infected 
cells. Therefore, by measuring the luminescence and plotting it against the concentrations, the 
EC50 values (concentration that resulted in 50% decrease in infected cells) for the target 
compounds can be determined (Figure 11, Scheme 13).  
 
 
Scheme 13. Enzymatic oxidation of 54 to 55 
 
4.6 Results and discussion 
4.6.1 Anti-viral activity against the CHIKV 
An overview of the anti-viral activities for the target compounds is shown in Graph 3. 
With the exception of 11, 12 and 17, all the compounds were significantly more active than 
the positive control, naringenin (51). Compounds 15 and 16 were the 2 most active lead 




to each other whereby both compounds have a benzylamide substituent and the 3-bromo-4-
methoxy substitution pattern on either aromatic ring A or B (Table 6).  
 
Graph 3. Overview of the anti-CHIKV activity of target compounds 
 
4.6.1.1 Validating the anti-CHIKV activities of lead compounds 
The validity of the EC50 values obtained is dependent on the toxic effect of the lead 
compounds 15 and 16 to the cells at their EC50 values. To ensure the anti-viral activities of 15 
and 16 are not a result of cell death, the cell viability/infectivity against concentration for 
both compounds were plotted (Graph 4). For both plots, at the EC50 values of 15 and 16, the 
percentage of cells relative to untreated control remained at 100%. Therefore, both 15 and 16 
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Table 6. Ranking of target compounds in decreasing order of anti-CHIKV activity 
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Figure 12. Effect of bromination on anti-viral activity 
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4.6.1.3 Importance of the 3-bromo-4-methoxy substitution pattern 
 The importance of the 3-bromo-4-methoxy substitution pattern can be emphasized 
when we compare the EC50 values of 11, 16 and 21 (Figure 14). Anti-viral activity improved 
when comparing EC50 values of compound 11 (un-substituted aromatic ring A) to a 4-
methoxy substituted one (compound 21) and finally to the lead compound 16 which is 3-
bromo-4-methoxy substituted. As already discussed above, anti-viral activity did not improve 
with a 3,5-dibromo-4-methoxy substituted aromatic ring A (compound 26). These studies 
suggest that the 3-bromo-4-methoxy substitution pattern is crucial for anti-viral activity. 
However at this stage, we are unable to determine if the anti-viral activity of 16 is due to the 
combined effect of both the methoxy and bromo group or due solely to the bromo group. The 
synthesis of a second generation of compound library with the compound containing the 3-
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Figure 14. Effect of substitution pattern on aromatic ring A with respect to anti-viral activity 
 
4.6.1.4 The effect of amide substituent 
To investigate the effect of the amide substituent (benzylamide, phenethylamide and 
phenylpropylamide) with respect to anti-viral activity, the target compounds were ranked in 
decreasing order of anti-viral activity within each series (Table 7, Table 8) and analyzed.  
In series 1, the most active compound, 13 has a phenylpropylamide substituent, 




has a benzylamide substituent. The opposite trend was observed for series 3 whereby the 
most active compound, 16 has a benzylamide substituent, followed by 22 with a 
phenethylamide substituent and lastly, the least active compound 23 which has the 
phenylpropylamide substituent (Table 7). 
Table 7. Compounds in series 1 and 3 ranked in decreasing anti-viral activity 
Opposite trend in series 1 and 3
 
 

































EC50 28.8 µM 
 
For compounds in series 4, similar EC50 values for 26, 27 and 28 suggest that the 
amide substituent have no effect on anti-viral activity. Lastly, no trend could be observed for 
compounds in series 2 (Table 8). Based on the observations above, we can only conclude that 
the effect of amide substituent depends on the substitution pattern on aromatic ring A. 
However, as the 2 best compounds 15 and 16 from our studies to date possess the 
benzylamide substituent suggest that amides with shorter alkyl chain length may be 




synthesize and test the analogue of 16, which has a phenyl ring connected directly to the 
amide nitrogen instead of a benzylamide (59, section 4.7, Table 11). 
Table 8. Compounds in series 2 and 4 ranked in decreasing anti-viral activity 
No observable trend in series 2 and 4































EC50 25.7 µM 
 
4.6.2 Toxicity 
 An overview of the in vitro toxicities of 11 - 30 is shown in Graph 5. In general, with 






Graph 5. Overview of the toxicities of first generation target compounds 
 
4.6.2.1 The effect of bromine atoms 
When the target compounds were ranked in increasing order of toxicity (Table 9), the 
most toxic compounds were the ones possessing bromine on either one or both of the 
aromatic rings A and B. In general, the least toxic compound, 21 and those in the moderate 
range of toxicities (CC50 479 – 222 µM) are non-brominated (with the exception of 20). It is 
also observed that toxicity is not proportional to the number of bromine present. 
The effect of bromination with respect to toxicity was investigated by comparing the 
toxicities of compounds in the benzylamide, phenethylamide and phenylpropylamide series 
with different substitution patterns on aromatic ring A (Figure 15, Figure 16). In the 
phenethylamide and phenylpropylamide series (Figure 15), toxicity increased when the 
aromatic ring A has a 4-methoxy group (17) and also with the addition of each bromine atom 
on aromatic ring A (22 and 27). However, in the benzylamide series (Figure 16), the 4-
methoxy substituted compound (21) was not toxic and there was no difference in toxicities 
between the mono and di-brominated compounds (26 and 16). Therefore, in this preliminary 
























bromides contribute to toxicity. There is ample scientific evidence that the aryl bromide 
moiety is a toxicophore, where it can undergo oxidative biotransformation with oxidative 
enzymes in the body to form reactive metabolites that can bond covalently to cellular proteins 
thus inducing toxicity.44, 45 We postulate that this may be the cause of toxicity observed in our 
study.  To try to reduce the toxicities of lead compounds 15 and 16 which are both 
brominated, the chlorinated analogue of 16 will be synthesized in the second generation 
library in hope that the aryl chloride moiety would be less toxic (61, section 4.7, Table 11).  
Table 9. Toxicity rank of target compounds based on CC50 values 
Least toxic compound, CC50 >1000 µM
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Figure 16. Benzylamide compounds – Toxicity vs substitution pattern 
 
4.6.2.2 The effect of amide substituent 
 To investigate the effect of the various amide substituents with respect to toxicity, the 
target compounds were ranked in increasing order of toxicity within each series with a 
constant aryl substituent on aromatic ring A (Table 10). For the non-brominated compounds 
in series 1 and series 2, toxicity increased in the order of benzylamide, phenethylamide and 
phenylpropylamide substituent (e.g. series 1, 11 vs 12 vs 13). However, for the brominated 
compounds in series 3 and series 4, no trend on the amide substituent on toxicity could be 
discerned. The observation that amide substituent have no effect on toxicity for the 
brominated compounds in series 3 and 4 suggests that bromination in aromatic ring A has a 
larger effect on toxicity. Thus if the compounds are non-brominated in ther aryl rings as in 
series 1 and 2, then having the benzylamide substituent (e.g. 11 and 21) would be optimal for 





Table 10. Increasing toxicities of compounds in series 1 - 4 
Same trend in series 1 and 2 
 
No observable trend in series 3 and 4
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4.7 Second generation compounds 
Based on the information gathered from the SAR and STR analyses thus far, a second 
generation of compound library was synthesized to further investigate structural features that 
are crucial for anti-viral activity and non-toxicity. In the second generation of compounds 
(Table 11), 7 analogues of the best compounds from the first library i.e. 15 and 16 were 
synthesized and tested for in vitro toxicities and anti-viral activities against CHIKV. 
Analogues 56 and 57 were designed to investigate if the anti-viral activity of best compound 
15 is as a result of the combination of the 3-bromo-4-methoxy substituent or if activity be 
retained in the presence of only the 4-methoxy or 3-bromo substituent on the aromatic ring B. 
Likewise, analogue 58 was synthesized to investigate if the anti-viral activity of compound 
16 can be retained with only the 3-bromo substituent on aromatic ring A. Analogue 59 was 




anti-viral activity since it was shown that the benzylamide derivatives (shorter compounds) 
gave better activities. To investigate the importance of an aryl group, the cyclohexyl analogue 
60 was synthesized. To try to reduce the toxicity of compound 16, its 3-chloro-4-methoxy 
analogue, 61 was synthesized. So far, all target compounds retained the oxime moiety. In 
order to investigate the role of oxime on anti-viral activity and toxicity, analogue 62, which 
has a methoxy-oxime moiety was synthesized and tested.  
 






15 56 57 
  
 
16 58 59 
 
  
 60 61 
   
  
 62  
 
 
4.8 Synthesis of second generation compounds 
 In general, compounds 56 – 61 were synthesized employing the same route as 
outlined in chapter 2.4, by employing the corresponding aldehydes as starting material and 




condensation of arylpyruvic acid 33iii with commercially available methoxyamine 
hydrochloride and sodium acetate in ethanol gave the methoxy-oxime acid 63, which was 















3 h, 140 °C
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Scheme 14. Synthetic route to 62 
 
4.9 Second generation compounds – anti-viral activity 
 With the second generation of compounds ready, we proceeded to test their anti-viral 
activities against CHIKV and toxicities using the in vitro anti-viral and cell viability assays as 
described in section 4.5. 
4.9.1 The combined effect of the 3-bromo-4-methoxy groups 
 In section 4.6.1.3, we discussed on the importance of the 3-bromo-4-methoxy 
substitution pattern on either of the aromatic ring A or B for anti-viral activity. However, it 
was not clear if the anti-viral activity is due to the combined or individual effect of the 3-
bromo and 4-methoxy groups. To address this query, second generation compounds 56 – 58 




 Comparing the EC50 values of compound 15 and its analogues 11, 56, 57, it was 
observed that having a 3-bromo group on ring B (57) resulted in greater improvement in anti-
viral activity than only having the 4-methoxy group (56). However, it is clear that both 3-
bromo and 4-methoxy groups contribute positively to the activity of 15. 
 In the case of the lead compound 16 and its analogues (11, 58 and 21), compounds 
having only the 3-bromo (58) or 4-methoxy (21) group in aromatic A exhibited similar anti-
viral activities. However it is clear that the combination of both the 3-bromo and 4-methoxy 
groups (16) are important for improving anti-viral activity. Hence, we conclude that the 
combined effect of both 3-bromo and 4-methxy groups is important for good anti-viral 
activity.  
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Figure 17. Effect of aromatic ring substitution pattern on anti-viral activity 
 
4.9.2 The effect of amide substituent 
In section 4.6.1.4, compound 59 was proposed for testing as it contained a phenyl ring 
directly connected to the amide nitrogen since it was observed earlier that “shorter” 
compounds are generally more active (for example lead compounds 15 and 16 which have 




the benzylamide substituent). Comparison of the EC50 values of 59, 22 and 23 which contain 
the anilide, phenethylamide and phenylpropylamide substituent respectively show similar 
EC50 values ( 
Figure 18). Only compound 16 bearing the benzylamide group remains the most 
active compound in this series. This discovery suggests that the target compounds with the 
benzylamide substituent are optimal for anti-viral activity. 
    
59 
EC50 26.0 µM 
16 
EC50 13.3 µM 
22 
EC50 25.4 µM 
23 
EC50 28.8 µM 
 
Figure 18. Effect of amide substituent on anti-viral activity 
 
4.9.3 The effect of aromatic ring B 
The anti-viral activity of the cyclohexylamide analogue 60 without the aromatic ring 
B was twice that of 59 (Figure 19). Therefore, we postulate that either 1) the aromatic amide 
is involved in some π-π stacking interactions for anti-viral activity or 2) the conformation of 
the amide substituent has to be planar.  
59 
EC50 26.0 µM 
60 
EC50 53.8 µM 
 





4.9.4 The role of free oxime on anti-viral activity 
Finally, to determine the role of the oxime moiety with respect to anti-viral activity, 
compound 62 was tested. Comparing the EC50 values of 16 and 62, anti-viral activity against 
CHIKV improved from 13.3 µM to 4.3 µM when the free oxime was replaced with an O-
methyl substituted oxime, implying that either lipophilic compounds improve activity by 
enhancing membrane permeability or the absence of the H-bond donor group in the oxime 
OH is a positive contributor to anti-viral activity. 
  
16 
EC50 13.3 µM 
cLogP 3.96 
62 
EC50 4.3 µM 
cLogP 4.72 
 
Figure 20. Comparing the EC50 values of 16 and 62 
 
4.9.5 Correlation of lipophilicity and anti-viral activity 
 To assess if there is a correlation between anti-viral activities and lipophilicity, the 
cLogP values of the compounds were plotted against the corresponding EC50 values as shown 
in Graph 6. From the graph, we see that although most of the compounds have EC50 values 
around 30 µM, they do not have similar cLogP values. Instead, the cLogP values are in the 
range from 3 to 6. The low coefficient of determination (R2 0.28) indicates a weak correlation 
between lipophilicity and anti-viral activity. Therefore, it is unlikely that the significant 





Graph 6. Plot of cLogP against EC50 values 
 
4.10 Second generation compounds – toxicity 
4.10.1 Effect of the 3-chloro and O-methyl substituted oxime 
 As discussed in section 4.6.2.1, the 3-chloro substituted analogue 61 of lead 
compound 16 was designed in an attempt to reduce toxicity. The presence of the chlorine 
atom instead of the bromine atom in compound 61 showed comparable EC50 values while the 
CC50 value was greatly reduced from 87.9 to 400.0 µM ( 
Figure 21). This result reaffirms our hypothesis that the bromine substituent contributes to 
toxicity. 
Interestingly,when the toxicities of 16 and 62 are compared, both of which have a 3-
bromo-4-methoxy substituted aromatic ring A, it was found that 62 is not toxic, with CC50 
value >1000 µM. As the only difference is the presence of an O-methyl substituted oxime 
instead of the free oxime moiety in 62, it is possible that other parameters are also important 
for toxicities. 
 



















EC50 13.3 µM 
CC50 87.9 µM 
cLogP 3.96 
61 
EC50 16.5 µM 
CC50 400.0 µM 
cLogP 3.81 
62 
EC50 4.3 µM 
CC50 >1000 µM 
cLogP 4.72 
 
Figure 21. Effect of the 3-chloro and O-methyl substituted oxime 
 
4.10.2 Correlation of lipophilicity and toxicity 
 The cLogP values of the compounds were plotted against the corresponding CC50 
values to assess if there is any correlation between lipophilicity and toxicity 
(  
Graph 7). From the plot, no correlation was observed as the majority of the compounds have 
CC50 values around 100 µM possess cLogP values ranging from 3 to 6. Together with the low 
coefficient of determination (R2 0.22), we conclude that there is no correlation between 
lipophilicity and toxicity.  



















Graph 7. Plot of cLogP against CC50 values 
 
4.11 Conclusion 
 In total, 27 tyrosine-oxime compounds were synthesized and tested for cytotoxicity 
and CHIKV inhibitory activity using the HEK293T cell viability assay and infectious clone 
cell-based assay. From our studies, key structural features needed for good anti-viral activity 
and toxicity were identified.  
Firstly, it was shown that the combination of the 3-bromo and 4-methoxy groups on 
the aromatic rings was optimal for anti-viral activity against CHIKV. It was however noted 
that substitution can only be tolerated at either aromatic ring A or B as substitution at both 
rings resulted in a loss in anti-viral activity. Secondly, the amide substituent is optimal with 
benzylamide in order for compounds to possess anti-viral activities. Compounds having an 
anilide, phenethylamide, phenylpropylamide or cyclohexylamide resulted in a complete loss 
of activities. Thirdly, an aromatic amide substituent as compared to a cyclic alkyl ring is 
important for maintaining activity. We postulate that anti-viral activity is either attributed by 
1) π- π stacking interactions by the aromatic amide substituent or 2) the planar structure of 
the aromatic ring. Fourthly, replacement of the free oxime with an O-methyl substituted 
oxime resulted in significant improvement in anti-viral activity and this suggests that either  1) 


















lipophilic compounds improve activity by enhancing membrane permeability or 2) the 
absence of the H-bond donor group on oxime moiety is advantageous. No correlation 
between lipophilicity and anti-viral activity was observed. Surprisingly, the O-methyl 
substituted oxime in 62 also greatly reduces toxicity. These studies also did not find any 
correlation between lipophilicity and toxicity.  
 
4.12 Future work 
 From our study, we have identified compound 62 to be the best compound as it is the 
most potent anti-viral agent without exhibiting any toxicity to the cells. To improve the 
potency of compound 62, the following third generation compounds are proposed (Table 12). 
Firstly, compounds to re-investigate the SAR and STR of the substitution pattern on both 
aromatic ring A and B together with an O-methyl substituted oxime will be synthesized. 
Secondly, to examine the generality of the discovery that O-methyl oxime showed potent 
anti-viral activity, compounds with various O-alkyl substituted oximes will be examined. 
Thirdly, to investigate the importance of aromatic amides for anti-viral activity as compared 
to cyclo-alkyl amides, compound containing a cyclohexylmethylamide, analogous to 15 
should be studied. Lastly, the necessity of an oxime moiety will also be examined by 
replacing it with a carbonyl group.   
 Due to the lack of individual enzyme based assays, CHIKV inhibitory mechanism of 
lead compound 62 has yet to be determined. However, in silico high-throughput screening of 
the 27 synthesized compounds with the identified nsP2 and nsP3 CHIKV proteins can be 
carried out. Results from the docking studies may shed light on the interactions between the 
ligand and binding pocket thus providing more information on modifying the lead compound 




Table 12. Proposed third generation compounds 
Lead compound Third generation compounds 
 
62 
EC50 4.3 µM 
CC50 >1000 µM 
 
To investigate the SAR of an O-methoxy 
substituted oxime with different substitution 
pattern on aromatic ring A and B. 
 
 
To investigate the SAR and H-bond acceptor 
strength of various O-alkyl substituted oximes 
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Appendix I - Experimental 
Chemistry: Materials and Methods 
 All reagents were purchased from Sigma Aldrich or Alfa Aesar and were used 
without further purification unless otherwise specified. Reactions involving air or moisture 
sensitive reagents were performed in dried glassware under nitrogen atmosphere. Dry DMF, 
Et2O and DCM were dried using a GlassContour Solvent Purification System. Dry EtOH was 
dried with 3 Å molecular sieves. All other solvents of Analytical (AR) and HPLC grades 
were used as such from the bottles. Thin layer chromatography (TLC) was performed on 
Merck pre-coated silica gel plates. Visualization was accomplished with UV light or by 
staining with KMnO4 or CAM solution. Compounds were purified by flash chromatography 
on column using Merck silica gel 60 (230-400 mesh) or semi-preparative HPLC with 
Phenomenex Gemini 5u C18 110 A (150 × 10.0 mm, 5 micron) on a Shimadzu system unless 
otherwise specified. Mass spectra were recorded by electron spray ionization on an Applied 
Biosystems MDS SCIEX API 2000 mass spectrometer or the electro spray ionization-time of 
flight mode on Agilent 6210 mass spectrometer. Analytical HPLC were performed with 
Phenomenex Kinetex 2.6u C18 100 AA (150 × 4.60 mm, 2.6 micron) column. Melting points 
were obtained on a Reichert hot stage apparatus and are uncorrected. NMR spectra were 
recorded at 400 MHz for 1H and at 100 MHz for 13C on a Bruker spectrometer with CDCl3 
and DMSO-d6 as solvent. The chemical shifts are given in ppm, using the proton solvent 
residue signal (CDCl3: δ 7.26; DMSO-d6: δ 2.50; Acetone-d6: δ 2.05; CD3OD: δ 3.34) as a 
reference in the 1H NMR. The deuterium coupled signal of the solvent was used as reference 
in 13C NMR (CDCl3: δ 77.16; DMSO-d6: δ 39.52). The following abbreviations were used to 
describe the signals: s = singlet, d = doublet, t = triplet, m = multiplet, brs = broad signal. 
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General procedure for the synthesis of azlactone 
 To a mixture of aldehyde (1.0 eq.), N-acetylglycine (1.3 eq.) and sodium acetate 
(1.3 eq.), acetic anhydride (0.45/mmol) was added and the resultant mixture was brought to 
reflux at 140 ˚C for 3 h. After cooling the mixture to room temperature, the solid was filtered, 
poured into ice-water and stirred vigorously for 30 min. The resultant solid was filtered and 
vacuum dried to yield the azalactone. The crude azlactone was used for the next step without 
further purification.  
(4Z)-2-methyl-4-(phenylmethylidene)-4,5-dihydro-1,3-oxazol-5-one 34i 
Azlactone 34i (Brown solid, quant.) was prepared from benzaldehyde 35i 
following the general procedure described earlier. Rf 0.70 (50% 
EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 8.09 - 8.06 (m, 2H, Ar), 7.45 – 
7.43 (m, 3H, Ar), 7.15 (s, 1H, CH), 2.41 (s, 3H, CH3); The spectroscopic data for this 
compound are consistent with literature data.46 
(4Z)-4-[(4-methoxyphenyl)methylidene]-2-methyl-4,5-dihydro-1,3-
oxazol-5-one 34ii 
Azlactone 34ii (Brown solid, quant.) was prepared from 4-
methoxybenzaldehyde 35ii following the general procedure described earlier. Rf 0.65 (50% 
EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 8.05 - 8.03 (m, 2H, Ar), 7.08 (s, 1H, CH), 6.95 – 
6.93 (m, 2H, Ar), 3.85 (s, 3H, OCH3), 2.37 (s, 3H, CH3); δC (100 MHz, CDCl3) 168.27, 
165.00, 162.18, 134.36, 131.57, 131.53, 126.27, 114.56, 55.54, 15.71; The spectroscopic data 
for this compound are consistent with literature data.47 
  





Azlactone 34iii (Brown solid, 88%) was prepared from 3-bromo-4-
methoxybenzaldehyde 35iii following the general procedure 
described earlier. Rf 0.26 (20% DCM/Pet. spirits); δH (400 MHz, 
CDCl3) 8.42 (m, 1H, Ar), 7.96 – 7.94 (m, 1H, Ar), 7.00 (s, 1H, CH), 6.95 – 6.93 (m, 1H, Ar), 
3.96 (s, 3H, OCH3), 2.40 (s, 3H, CH3);  δC (100 MHz, CDCl3) 167.94, 165.90, 158.18, 136.95, 
133.45, 131.69, 129.74, 127.54, 112.51, 111.87, 56.60, 15.84; The spectroscopic data for this 
compound are consistent with literature data.16 
(4Z)-4-[(3,5-dibromo-4-methoxyphenyl)methylidene]-2-methyl-4,5-
dihydro-1,3-oxazol-5-one 34iv 
Azlactone 34iv (Brown solid, 88%) was prepared from 3,5-
dibromo-4-methoxybenzaldehyde 35iv following the general 
procedure described earlier.  Rf 0.44 (10% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 8.26 (s, 
2H, Ar), 6.92 (s, 1H, CH), 3.94 (s, 3H, OCH3), 2.43 (s, 3H, CH3); The spectroscopic data for 
this compound are consistent with literature data.48 
(4Z)-4-[(3-chloro-4-methoxyphenyl)methylidene]-2-methyl-4,5-
dihydro-1,3-oxazol-5-one 34v 
Azlactone 34v (Brown solid, 67%) was prepared from 3-chloro-4-
methoxybenzaldehyde 35v following the general procedure described earlier. Rf 0.55 (50% 
EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 8.28 (d, 1H, Ar, J=2.0 Hz), 7.89 – 7.87 (dd, 1H, 
Ar, J=2.0, 8.6 Hz), 7.02 (s, 1H, CH), 6.98 – 6.96 (d, 1H, Ar, J=8.6 Hz), 3.97 (s, 3H, OCH3), 
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2.40 (s, 3H, CH3);  δC (100 MHz, CDCl3) 167.92, 165.86, 157.32, 133.73, 132.75, 131.69, 
129.86, 127.01, 123.40, 112.00, 56.46, 15.79. 
General procedure for the hydrolysis of azlactone to arylpyruvic acid 
 To a flask of azlactone (1.0 eq.) was added acetone and 3N HCl (1:1, 0.1 M) and the 
resulting mixture was refluxed at 75 ˚C. After 12 h, acetone was removed in vacuo and the 
residue partitioned between EtOAc and H2O. The organic layer was separated and the 
aqueous layer was extracted 3 times with EtOAc. The combined organic extracts were 
washed with brine, dried with anhydrous Na2SO4 and concentrated in vacuo to give the 
arylpyruvic acid. The crude arylpyruvic acid was used for the next step without further 
purification. 
3-Phenyl-2-hydroxyacrylic acid 33i 
Acid 33i (Brown solid, quant.) was prepared from azlactone 34i following the general 
procedure described earlier.  Rf 0.27 (3% MeOH/EtOAc); δH (400 MHz, DMSO) 7.76 – 7.74 
(m, 2H, Ar), 7.36 – 7.32 (m, 2H, Ar), 7.24 – 7.20 (m, 1H, Ar), 6.39 (s, 1H, CH); δC (100 MHz, 
DMSO) 166.27, 141.93, 134.94, 129.17, 128.24, 127.05, 109.29. 
3-(4-Methoxyphenyl)-2-hydroxyacrylic acid 33ii 
Acid 33ii (Yellow solid, 92%) was prepared from azlactone 34ii 
following the general procedure described earlier.  Rf 0.12 (50% 
EtOAc/Pet. spirits); δH (400 MHz, DMSO) 7.72 – 7.69 (m, 2H, Ar), 6.93 – 6.91 (m, 2H, Ar), 
6.37 (s, 1H, CH), 3.76 (s, 3H, OCH3); The spectroscopic data for this compound are 
consistent with literature data.47 
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3-(3-Bromo-4-methoxyphenyl)-2-hydroxyacrylic acid 33iii 
Acid 33iii (Brown solid, quant.) was prepared from azlactone 34iii 
following the general procedure described earlier.  Rf 0.10 (50% 
EtOAc/Pet. spirits); δH (400 MHz, DMSO) 8.10 (m, 1H, Ar), 7.68 – 7.65 (dd, 1H, Ar, J=8.0, 
4.0 Hz), 7.10 (d, 1H, Ar, J=8.0 Hz), 6.35 (s, 1H, CH), 3.85 (s, 3H, OCH3); The spectroscopic 
data for this compound are consistent with literature data.16 
3-(3,5-Dibromo-4-methoxyphenyl)-2-hydroxyacrylic acid 33iv 
Acid 33iv (Brown solid, quant.) was prepared from azlactone 34iv 
following the general procedure described earlier. Rf 0.10 (50% 
EtOAc/Pet. spirits); δH (400 MHz, DMSO) 8.06 (s, 2H, Ar), 6.35 (s, 1H, CH), 3.80 (s, 3H, 
OCH3); The spectroscopic data for this compound are consistent with literature data.49 
3-(3-Chloro-4-methoxyphenyl)-2-hydroxyacrylic acid 33v 
Acid 33v (Brown solid, 79%) was prepared from Azlactone 34v following the general 
procedure described earlier.  Rf 0.10 (50% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.84 (m, 
1H, Ar), 7.60 – 7.51 (m, 1H, Ar), 6.90 (m, 1H, Ar), 6.44 (s, 1H, CH), 3.90 (s, 3H, OCH3).  
 
General procedure for the synthesis of PMB oxime acid 
 To a mixture of arylpyruvic acid (1.0 eq.), O-(p-methoxybenzyl) hydroxylamine 
hydrochloride (1.5 eq.) and NaOAc (3.0 eq.) was added EtOH (0.1 M) and stirred at room 
temperature for 12 h. Thereafter, EtOH was removed in vacuo and the residue partitioned 
between EtOAc and 3N HCl. The organic layer was separated and the aqueous layer was 
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extracted 3 times with EtOAc. The combined organic extracts were washed with brine and 
dried with anhydrous Na2SO4. The solvent was removed in vacuo and the residue was 
purified by flash column chromatography (50% EtOAc/Pet. spirits) to give the OPMB oxime 
acid.  
(2E)-2-{[(4-methoxyphenyl)methoxy]imino}-3-phenylpropanoic acid32i   
Acid 32i (Brown solid, 89%) was prepared from arylpyruvic acid 33i 
following the general procedure described earlier.  Rf 0.24 (50% 
EtOAc/Pet. spirits); δH (400 MHz, DMSO) 7.28 – 7.19 (m, 5H, Ar), 
7.15 – 7.14 (m, 2H, Ar), 6.93 – 6.90 (m, 2H, Ar), 5.17 (s, 2H, OCH2), 3.81 (s, 2H, CH2), 3.75 
(s, 3H, OCH3);  δC (100 MHz, DMSO) 164.39, 159.16, 151.12, 136.00, 129.90, 128.80, 
128.67, 128.39, 126.35, 113.75, 76.28, 55.08, 30.77.  
(2E)-3-(4-methoxyphenyl)-2-{[(4-
methoxyphenyl)methoxy]imino}propanoic acid 32ii 
Acid 32ii (Brown solid, 74%) was prepared from arylpyruvic 
acid 33ii following the general procedure described earlier.  Rf 0.14 (50% EtOAc/Pet. spirits); 
δH (400 MHz, DMSO) 7.29 – 7.27 (m, 2H, Ar), 7.07 – 7.05 (m, 2H, Ar), 6.93 – 6.91 (m, 2H, 
Ar), 6.82 – 6.79 (m, 2H, Ar), 5.15 (s, 2H, OCH2), 3.75 (s, 3H, OCH3), 3.72 (s, 2H, CH2), 3.70 
(s, 3H, OCH3); δC (100 MHz, DMSO) 164.00, 159.09, 157.75, 129.82, 129.65, 128.90, 
127.86, 113.76, 113.72, 76.07, 55.05, 54.97, 29.89 (one carbon not seen). 
(2E)-3-(3-bromo-4-methoxyphenyl)-2-{[(4-methoxyphenyl)methoxy]imino}propanoic acid 
32iii 
Acid 32iii (Brown solid, 75%) was prepared from arylpyruvic 
acid 33iii following the general procedure described earlier.  Rf 
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0.14 (50% EtOAc/Pet. spirits); δH (400 MHz, DMSO) 7.32 (m, 1H, Ar), 7.29 – 7.27 (m, 2H, 
Ar), 7.13 – 7.10 (m, 1H, Ar), 6.99 – 6.98 (m, 1H, Ar), 6.93 – 6.91 (m, 2H, Ar), 5.17 (s, 2H, 
OCH2), 3.79 (s, 3H, OCH3), 3.75 (s, 3H, OCH3), 3.73 (s, 2H, CH2); δC (100 MHz, DMSO) 
164.36, 159.19, 154.02, 151.13, 132.90, 129.95, 129.67, 129.00, 128.77, 113.82, 112.62, 
110.33, 76.36, 56.17, 55.09, 29.53. 
(2E)-3-(3,5-dibromo-4-methoxyphenyl)-2-{[(4-
methoxyphenyl)methoxy]imino}propanoic acid 32iv 
Acid 32iv (Brown solid, 70%) was prepared from arylpyruvic 
acid 33iv following the general procedure described earlier.  Rf 
0.25 (50% EtOAc/Pet. spirits); δH (400 MHz, DMSO) 7.38 (s, 2H, Ar), 7.27 (d, 2H, Ar, J=8 
Hz), 6.92 (d, 2H, Ar, J=8 Hz), 5.18 (s, 2H, OCH2), 3.76 (s, 3H, OCH3), 3.75 (s, 3H, OCH3), 
3.75 (s, 2H, CH2); δC (100 MHz, DMSO) 163.35, 159.13, 151.93, 150.08, 135.46, 132.80, 
129.93, 128.54, 117.20, 113.81, 76.54, 60.37, 55.08, 29.48; The spectroscopic data for this 
compound are consistent with literature data.19 
(2E)-3-(3-chloro-4-methoxyphenyl)-2-{[(4-
methoxyphenyl)methoxy]imino}propanoic acid 32v 
Acid 32v (Brown solid, 85%) was prepared from arylpyruvic 
acid 33v following the general procedure described earlier.  Rf 
0.14 (50% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.28 – 7.26 (m, 3H, Ar), 7.12 – 7.09 (m, 
1H, Ar), 6.92 – 6.9 (m, 2H, Ar), 6.79 – 6.77 (m, 1H, Ar), 5.23 (s, 2H, OCH2), 3.85 (s, 3H, 
OCH3), 3.82 (s, 3H, OCH3), 3.80 (s, 2H, CH2); δC (100 MHz, CDCl3) 162.63, 160.17, 154.08, 
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149.75, 131.16, 130.44, 128.78, 128.23, 127.77, 122.44, 114.28, 112.21, 78.45, 56.31, 55.46, 
29.28. 
(2E)-3-(3-bromophenyl)-2-{[(4-methoxyphenyl)methoxy]imino}propanoic acid 32vi 
Acid 32vi (Yellow solid, quant.) was prepared from arylpyruvic acid 
33vi following the general procedure described earlier.  Rf 0.14 (50% 
EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.38 (m, 1H, Ar), 7.34 – 
7.32 (m, 1H, Ar), 7.28 – 7.26 (m, 2H, Ar), 7.17 – 7.15 (m, 1H, Ar), 7.12 – 7.10 (m, 1H, Ar), 
6.92 – 6.90 (m, 2H, Ar), 5.24 (s, 2H, OCH2), 3.86 (s, 2H, CH2), 3.82 (s, 3H, OCH3); δC (100 
MHz, CDCl3) 163.39, 160.00, 149.24, 137.36, 132.24, 130.30, 130.04, 129.96, 127.93, 
127.66, 122.47, 114.14, 78.34, 55.32, 30.06. 
3-(3-Bromo-4-methoxy-phenyl)-2-methoxyimino-propionic acid 63 
Acid 63 (Brown solid, quant.) was prepared from arylpyruvic acid 33iii following the general 
procedure described earlier.  Rf 0.05 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.44 (m, 
1H, Ar), 7.19 – 7.17 (m, 1H, Ar), 6.80 – 6.78 (m, 1H, Ar), 4.11 (s, 3H, CH3), 3.85 (s, 3H, 
OCH3), 3.81 (s, 2H, CH2); δC (100 MHz, CDCl3) 163.90, 154.93, 149.53, 133.99, 129.42, 
128.78, 112.08, 111.70, 64.08, 56.37, 29.18. 
 
General procedure for amide bond formation 
 To a stirred solution of OPMB acid (1.0 eq.) in DMF (0.1 M) were added N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (1.1 eq.), 1-hydroxybenzotriazole 
hydrochloride (1.1 eq.) and diisopropylethylamine (2.5 eq.). After stirring at room 
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temperature for 5 min, amine (1.1 eq.) was added and stirred at room temperature. After 12 h, 
the mixture was partitioned between H2O and EtOAc. The organic layer was separated and 
the aqueous layer was extracted 3 times with EtOAc. The combined organic extracts were 
washed with brine, dried over NasSO4 and concentrated in vacuo. The residue was purified by 
flash column chromatography (25% EtOAc/Pet. spirits) to yield the amide.    
(2E)-N-benzyl-2-{[(4-methoxyphenyl)methoxy]imino}-3-
phenylpropanamide 31i1 
Amide 31i1 (Yellow oil, 61%) was prepared from OPMB acid 
32i following the general procedure described earlier.  Rf 0.71 (50% EtOAc/Pet. spirits); δH 
(400 MHz, CDCl3) 7.42 – 7.28 (m, 12H, Ar), 7.10 (m, 1H, NH), 6.94 (m, 2H, Ar), 5.19 (s, 
2H, OCH2), 4.56 (d, 2H, NCH2, J=6.4 Hz), 4.05 (s, 2H, CH2), 3.88 (s, 3H, OCH3); δC (100 
MHz, CDCl3) 162.79, 159.76, 152.49,138.20, 136.41, 130.04, 129.54, 128.89, 128.83, 128.51, 
127.81, 127.62, 126.49, 114.00, 76.91, 55.41, 43.54, 30.23.  
(2E)-2-{[(4-methoxyphenyl)methoxy]imino}-3-phenyl-N-(2-phenylethyl)propanamide 31i2 
Amide 31i2 (Yellow oil, 77%) was prepared from OPMB acid 
32i following the general procedure described earlier.  Rf 0.25 
(25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.34 – 7.18 
(m, 12H, Ar), 6.91 – 6.89 (m, 2H, Ar), 6.78 (t, 1H, NH, J=5.6 Hz),  5.11 (s, 2H, OCH2), 3.96 
(s, 2H, CH2), 3.84 (s, 3H, OCH3), 3.56 (apparent q, 2H, NCH2), 2.85 (apparent t, 2H, CH2); 
δC (100 MHz, CDCl3) 162.70, 159.72, 152.53, 138.96, 136.43, 130.01, 129.48, 129.04, 
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Amide 31i3 (Yellow oil, 68%) was prepared from OPMB 
acid 32i following the general procedure described earlier.  
Rf 0.25 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 
7.34 – 7.28 (m, 12H, Ar), 7.00 – 6.99 (m, 2H, Ar), 6.82 (m, 1H, NH),  5.24 (s, 2H, OCH2), 
4.05 (s, 2H, CH2), 3.92 (s, 3H, OCH3), 3.43 (apparent q, 2H, NCH2), 2.74 (apparent t, 2H, 
CH2), 1.97 (m, 2H, CH2); δC (100 MHz, CDCl3) 162.69, 159.69, 152.55, 141.44, 136.42, 
129.92, 129.47, 128.97, 128.54, 128.46, 128.43, 126.39, 126.08, 113.95, 76.84, 55.36, 39.10, 
33.30, 31.17, 30.09. 
(2E)-N-[(3,5-dibromo-4-methoxyphenyl)methyl]-2-{[(4-methoxyphenyl)methoxy]imino}-3-
phenylpropanamide 31i4 
Amide 31i4 (Yellow oil, 77%) was prepared from OPMB 
acid 32i following the general procedure described earlier.  
Rf 0.71 (50% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 
7.40 (s, 2H, Ar), 7.28 – 7.17 (m, 7H, Ar), 7.03 (t, 1H, NH, J=6.4 Hz), 6.90 - 6.87 (m, 2H, Ar), 
5.14 (s, 1H, OCH2), 4.40 (d, 2H, NCH2, J=6.4 Hz),  3.95 (s, 2H, CH2), 3.87 (s, 3H, OCH3), 
3.82 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.93, 159.81, 153.58, 152.31, 137.01, 136.20, 





Amide 31i5 (Brown solid, 48%) was prepared from OPMB 
acid 32i following the general procedure described earlier.  Rf 0.27 (25% EtOAc/Pet. spirits); 
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δH (400 MHz, CDCl3) 7.45 (m, 1H, Ar), 7.29 – 7.16 (m, 7H, Ar), 7.96 (t, 1H, NH, J=6.0 Hz), 
6.89 - 6.83 (m, 4H, Ar), 5.12 (s, 2H, OCH2), 4.40 (d, 2H, NCH2, J=6.0 Hz),  3.95 (s, 2H, 
CH2), 3.88 (s, 3H, OCH3), 3.82 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.75, 159.78, 155.45, 
152.43, 136.35, 132.78, 131.91, 130.01, 129.50, 128.7, 128.52, 128.12, 126.51, 114.02, 
112.15, 111.93, 56.46, 55.43, 42.46, 30.20, 14.34.  
(2E)-N-[(4-methoxyphenyl)methyl]-2-{[(4-methoxyphenyl)methoxy]imino}-3-
phenylpropanamide 31i6 
Amide 31i6 (Brown solid, 61%) was prepared from OPMB 
acid 32i following the general procedure described earlier.  
Rf 0.22 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 
7.37 – 7.23 (m, 9H, Ar), 7.04 (t, 1H, NH, J=5.6 Hz), 6.94 - 6.91 (m, 4H, Ar), 5.16 (s, 2H, 
OCH2), 4.49 (d, 2H, NCH2, J=5.6 Hz),  4.03 (s, 2H, CH2), 3.85 (s, 3H, OCH3), 3.84 (s, 3H, 
OCH3); δC (100 MHz, CDCl3) 162.57, 159.67, 159.09, 152.45, 136.36, 130.21, 129.90, 
129.44, 129.08, 128.82, 128.39, 126.37, 114.12, 113.90, 77.04, 55.30, 55.28, 42.94 (one 
carbon not seen).  
(2E)-N-[(3-bromophenyl)methyl]-2-{[(4-
methoxyphenyl)methoxy]imino}-3-phenylpropanamide 31i7 
Amide 31i7 (Brown solid, 30%) was prepared from OPMB acid 
32i following the general procedure described earlier.  Rf 0.46 
(25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.40 (m, 2H, Ar), 7.28 – 7.17 (m, 9H, Ar), 
7.01 (m, 1H, NH), 6.89 - 6.88 (m, 2H, Ar), 5.12 (s, 2H, OCH2), 4.46 (d, 2H, NCH2,  
J=6.4 Hz),  3.95 (s, 2H, CH2), 3.81 (s, 3H, OCH3), 3.82 (s, 3H, OCH3). 
  





Amide 31ii1 (Yellow oil, 82%) was prepared from OPMB 
acid 32ii following the general procedure described earlier.  
Rf 0.73 (50% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 
7.28 – 7.16 (m, 9H, Ar), 7.01 (t, 1H, NH, J=6.0 Hz), 6.83 – 6.81 (m, 2H, Ar), 6.74 – 6.72 (m, 
2H, Ar), 5.05 (s, 2H, OCH2), 4.42 (d, 2H, NCH2, J=6.0 Hz), 3.86 (s, 2H, CH2), 3.73 (s, 3H, 
OCH3), 3.67 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.76, 159.67, 158.23, 152.71, 138.16, 





Amide 31ii2 (Yellow oil, 76%) was prepared from 
OPMB acid 32ii following the general procedure described earlier.  Rf 0.77 (50% EtOAc/Pet. 
spirits); δH (400 MHz, CDCl3) 7.32 – 7.17 (m, 9H, Ar), 6.90 – 6.88 (m, 2H, Ar), 6.80 – 6.77 
(m, 3H, Ar+NH),  5.09 (s, 2H, OCH2), 3.88 (s, 2H, CH2), 3.82 (s, 3H, OCH3), 3.76 (s, 3H, 
OCH3), 3.54 (apparent q, 2H, NCH2), 2.82 (apparent t, 2H, CH2); δC (100 MHz, CDCl3) 
162.72, 159.69, 158.24, 152.78, 138.94, 130.50, 130.00, 129.04, 128.90, 128.68, 128.43, 
126.57, 113.94, 113.86, 76.91, 55.35, 55.29, 40.72, 35.77, 29.15. 
  





Amide 31ii3 (Yellow oil, 77%) was prepared from 
OPMB acid 32ii following the general procedure 
described earlier.  Rf 0.75 (50% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.29 – 7.15 (m, 
9H, Ar), 6.90 – 6.88 (m, 2H, Ar), 6.78 – 6.75 (m, 2H, Ar), 6.68 (m, 1H, NH),  5.12 (s, 2H, 
OCH2), 3.86 (s, 2H, CH2), 3.81 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.31 (apparent q, 2H, 
NCH2), 2.63 (apparent t, 2H, CH2), 1.90 – 1.81 (m, 2H, CH2); δC (100 MHz, CDCl3) 162.78, 
159.74, 158.26, 152.88, 141.50, 130.58, 130.00, 129.06, 128.58, 128.58, 126.13, 114.01, 




Amide 31ii4 (Yellow oil, 80%) was prepared from 
OPMB acid 32ii following the general procedure described earlier.  Rf 0.27 (25% EtOAc/Pet. 
spirits); δH (400 MHz, CDCl3) 7.38 (m, 2H, Ar), 7.26 – 7.24 (m, 2H, Ar), 7.21 – 7.19 (m, 2H, 
Ar), 7.03 (t, 1H, NH, J=6.4 Hz), 6.91 - 6.88 (m, 2H, Ar), 6.80 – 6.77 (m, 2H, Ar), 5.14 (s, 1H, 
OCH2), 4.38 (d, 2H, NCH2, J=6.4 Hz),  3.88 (s, 2H, CH2), 3.86 (s, 3H, OCH3), 3.82 (s, 3H, 
OCH3), 3.77 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.97, 159.80, 158.34, 153.55, 152.59, 
137.03, 131.77, 130.50, 130.03, 128.80, 128.21, 118.40, 114.04, 113.98, 76.84, 60.75, 55.43, 
55.36, 41.91, 29.26.  





Amide 31ii5 (Brown solid, 65%) was prepared from 
OPMB acid 32ii following the general procedure 
described earlier.  Rf 0.23 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.44 (m, 1H, Ar), 
7.27 – 7.15 (m, 5H, Ar), 6.94 (t, 1H, NH, J=6.4 Hz), 6.89 - 6.87 (m, 2H, Ar), 6.85 – 6.83 (m, 
1H, Ar), 6.85 – 6.77 (m, 2H, Ar), 5.12 (s, 1H, OCH2), 4.39 (d, 2H, NCH2, J=6.4 Hz), 3.88 (s, 
5H, OCH3 + CH2), 3.82 (s, 3H, OCH3), 3.77 (s, 3H, OCH3); δC (100 MHz, CDCl3) 158.32, 
152.72, 132.76, 131.91, 130.55, 130.03, 128.90, 128.37, 128.10, 114.02, 113.94, 112.14, 
56.45, 55.24, 55.37, 42.43, 29.27. 
(2E)-N-benzyl-3-(3-bromo-4-methoxyphenyl)-2-{[(4-
methoxyphenyl)methoxy]imino}propanamide 31iii1 
Amide 31iii1 (White solid, 60%) was prepared from 
OPMB acid 32iii following the general procedure 
described earlier.  Rf 0.72 (50% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.54 (m, 1H, Ar), 
7.40 – 7.26 (m, 8H, Ar), 7.10 (t, 1H, NH, J=6.0 Hz), 6.96 – 6.93 (m, 2H, Ar), 6.82 – 6.80 (m, 
1H, Ar), 5.16 (s, 2H, OCH2), 4.54 (d, 2H, NCH2, J=6.0 Hz), 3.92 (s, 2H, CH2), 3.88 (s, 3H, 
OCH3), 3.85 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.55, 159.80, 154.56, 152.07, 138.11, 
134.20, 130.15, 129.96, 129.68, 128.81, 128.62, 127.75, 127.61, 114.08, 111.91, 111.43, 
76.91, 56.31, 55.37, 43.51, 28.88.  
  





Amide 31iii2 (Yellow oil, 67%) was prepared from 
OPMB acid 32iii following the general procedure 
described earlier.  Rf 0.66 (50% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.49 (m, 1H, Ar), 
7.35 – 7.20 (m, 8H, Ar+NH), 6.93 – 6.91 (m, 2H, Ar), 6.79 – 6.77 (m, 2H, Ar), 5.12 (s, 2H, 
OCH2), 3.87 (s, 3H, OCH3), 3.86 (s, 2H, OCH2), 3.85 (s, 3H, OCH3), 3.58 (apparent q, 2H, 
NCH2), 2.86 (apparent t, 2H, CH2); δC (100 MHz, CDCl3) 162.51, 159.80, 154.56, 152.13, 
138.90, 134.17, 130.16, 130.02, 129.66, 128.92, 128.81, 128.74, 126.64, 114.09, 111.92, 




Amide 31iii3 (Yellow oil, 85%) was prepared from 
OPMB acid 32iii following the general procedure described earlier.  Rf 0.88 (50% EtOAc/Pet. 
spirits); δH (400 MHz, CDCl3) 7.46 (m, 1H, Ar), 7.36 – 7.15 (m, 8H, Ar), 6.92 – 6.89 (m, 2H, 
Ar), 6.76 – 6.74 (m, 1H, Ar), 6.69 (t, 1H, NH, J=8.0 Hz),  5.12 (s, 2H, OCH2), 3.84 (s, 3H, 
OCH3), 3.82 (s, 2H, OCH2), 3.81 (s, 3H, OCH3), 3.31 (apparent q, 2H, NCH2), 2.64 (apparent 
t, 2H, CH2), 1.90 – 1.83 (m, 2H, CH2); δC (100 MHz, CDCl3) 162.56, 159.86, 154.61, 152.25, 
141.46, 134.26, 130.12, 130.09, 129.67, 128.82, 127.60, 127.50, 126.15, 114.15, 111.97, 
111.49, 76.84, 56.37, 55.43, 39.19, 33.36, 31.20, 28.84. 





Amide 31iii4 (Yellow oil, 85%) was prepared from 
OPMB acid 32iii following the general procedure 
described earlier.  Rf 0.70 (50% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.46 (m, 1H, Ar), 
7.40 (s, 2H, Ar), 7.28 – 7.25 (m, 2H, Ar), 7.20 – 7.18 (m, 1H, Ar), 7.03 (t, 1H, NH, J=4.0, 
8.0 Hz), 6.92 - 6.90 (m, 2H, Ar), 6.78 – 6.76 (m, 1H, Ar), 5.15 (s, 1H, OCH2), 4.40 (d, 2H, 
NCH2, J=4.0 Hz), 3.87 (s, 3H, OCH3), 3.85 (s, 5H, OCH3+CH2), 3.82 (s, 3H, OCH3); δC (100 
MHz, CDCl3) 162.76, 159.91, 154.69, 153.64, 151.94, 136.93, 134.24, 131.85, 130.19, 





Amide 31iii5 (Pale-yellow solid, 58%) was prepared 
from OPMB acid 32iii following the general procedure described earlier.  Rf 0.46 (25% 
EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.46 (m, 2H, Ar), 7.45 – 7.16 (m, 4H, Ar), 6.95 (t, 
1H, NH, J=6.0 Hz), 6.92 - 6.90 (m, 2H, Ar), 6.89 – 6.84 (m, 1H, Ar), 6.78 – 6.75 (m, 1H, Ar), 
5.12 (s, 1H, OCH2), 4.40 (d, 2H, NCH2, J=6.0 Hz), 3.88 (s, 3H, OCH3), 3.85 (s, 5H, 
OCH3+CH2), 3.82 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.57, 159.86, 155.47, 154.63, 
152.06, 134.24, 132.78, 131.82, 130.17, 129.92, 129.66, 128.64, 128.13, 114.15, 112.17, 
111.98, 111.93, 111.49, 76.84, 56.45, 56.38, 55.44, 42.48, 28.89. 





Amide 31iii6 (White solid, 22%) was prepared from OPMB 
acid 32iii following the general procedure described earlier.  
Rf 0.72 (50% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.57 – 7.54 (m, 2H, Ar), 7.49  (m, 
1H, Ar), 7.35 – 7.31 (m, 5H, Ar), 7.25 – 7.23 (m, 1H, Ar), 7.11 (brs, 1H, NH), 6.94 – 6.91 (m, 
2H, Ar), 6.76 – 6.74 (m, 1H, Ar), 5.22 (s, 2H, OCH2), 3.89 (s, 2H, CH2), 3.84 (s, 3H, OCH3), 
3.83 (s, 3H, OCH3); δC (100 MHz, CDCl3) 160.57, 154.68, 152.30, 134.30, 130.29, 129.72, 
129.19, 128.54, 124.53, 119.90, 114.23, 112.00, 77.67, 56.39, 55.47, 28.60.  
3-(3-Bromo-4-methoxy-phenyl)-N-cyclohexyl-2-(4-methoxy-benzyloxyimino)-propionamide 
31iii7 
Amide 31iii7 (White solid, 95%) was prepared from OPMB 
acid 32iii following the general procedure described earlier.  
Rf 0.72 (50% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.46 
(m, 1H, Ar), 7.82 – 7.26 (m, 2H, Ar), 7.21 – 7.18 (m, 1H, Ar), 6.92 – 6.90 (m, 2H, Ar), 6.75 
(m, 1H, Ar), 6.58 (d, 1H, NH, J=8.4 Hz), 5.13 (s, 2H, OCH2), 3.84 (s, 3H, OCH3), 3.82 (s, 
3H, OCH3), 3.81 (s, 2H, CH2), 1.93 – 1.89 (m, 2H, CH2), 1.72 – 1.68 (m, 2H, CH2), 1.59 (m, 
2H, CH2), 1.38 – 1.35 (m, 2H, CH2), 1.19 – 1.16 (m, 3H, CH+CH2); δC (100 MHz, CDCl3) 
161.51, 159.78, 154.48, 152.26, 134.27, 130.14, 129.68, 128.70, 114.06, 111.86, 111.34, 
77.19, 56.30, 55.38, 48.38, 33.02, 28.79, 25.61, 24.87 (one carbon not seen). 
  





Amide 31iv1 (White solid, 64%) was prepared from 
OPMB acid 32iv following the general procedure 
described earlier.  Rf 0.74 (50% EtOAc/Pet. spirits); δH 
(400 MHz, CDCl3) 7.47 (s, 2H, Ar), 7.38 – 7.28 (m, 7H, Ar), 7.07 (t, 1H, NH, J=6.0 Hz), 
6.94 – 6.92 (m, 2H, Ar), 5.14 (s, 2H, OCH2), 4.54 (d, 2H, NCH2, J=6.0 Hz), 3.87 (s, 5H, 
OCH3 + CH2), 3.84 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.31, 159.94, 152.78, 151.18, 
138.02, 135.01, 133.66, 130.29, 128.91, 128.38, 127.84, 127.74, 117.90, 114.22, 76.91, 60.71, 




Amide 31iv2 (Yellow oil, 75%) was prepared from 
OPMB acid 32iv following the general procedure described earlier.  Rf 0.77 (50% EtOAc/Pet. 
spirits); δH (400 MHz, CDCl3) 7.48 (s, 2H, Ar), 7.41 – 7.28 (m, 7H), 6.99 – 6.97(m, 2H, Ar), 
6.84 (t, 1H, NH, J=6.0 Hz), 5.17 (s, 2H, OCH2), 3.92 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 
3.88 (s, 2H, OCH2), 3.65 (apparent q, 2H, NCH2), 2.93 (apparent t, 2H, CH2); δC (100 MHz, 
CDCl3) 162.23, 159.91, 152.75, 151.20, 138.84, 135.04, 133.62, 130.28, 128.94, 128.79, 
128.55, 126.73, 117.87, 114.20, 76.91, 60.70, 55.45, 40.83, 35.80, 28.76. 
  





Amide 31iv3 (Yellow oil, 69%) was prepared from 
OPMB acid 32iv following the general procedure 
described earlier.  Rf 0.88 (50% EtOAc/Pet. spirits); 
δH (400 MHz, CDCl3) 7.38 (s, 2H, Ar), 7.37 – 7.25 (m, 7H, Ar), 7.00 – 6.97 (m, 2H, Ar), 6.77 
(t, 1H, NH, J=6.0 Hz),  5.20 (s, 2H, OCH2), 3.91 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.88 (s, 
2H, OCH2), 3.41 (apparent q, 2H, NCH2), 2.73 (apparent t, 2H, CH2), 2.00 – 1.92 (apparent 
quintet, 2H, CH2); δC (100 MHz, CDCl3) 162.24, 159.93, 152.74, 151.27, 141.40, 135.05, 
133.64, 130.23, 128.62, 128.50, 126.18, 117.84, 114.22, 76.84, 60.70, 55.44, 39.24, 33.37, 




Amide 31iv4 (White solid, 68%) was prepared from 
OPMB acid 32iv following the general procedure described earlier.  Rf 0.70 (50% EtOAc/Pet. 
spirits); δH (400 MHz, CDCl3) 7.42 – 7.41 (m, 4H, Ar), 7.27 – 7.25 (m, 2H, Ar), 7.04 (t, 1H, 
NH, J=6.4 Hz), 6.93 - 6.90 (m, 2H, Ar), 5.15 (s, 1H, OCH2), 4.41 (d, 2H, NCH2, J=6.4 Hz), 
3.87 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.82 (s, 5H, OCH3 + CH2); δC (100 MHz, CDCl3) 
162.43, 150.96, 136.79, 134.77, 133.63, 131.91, 130.29, 118.51, 117.95, 114.27, 76.84, 60.79, 
60.72, 55.46, 42.08, 28.82. 





Amide 31iv5 (Yellow oil, 68%) was prepared from 
OPMB acid 32iv following the general procedure 
described earlier.  Rf 0.35 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.47 - 7.46 (m, 1H, 
Ar), 7.42 (s, 2H, Ar), 7.26 – 7.18 (m, 3H, Ar), 6.96 (t, 1H, NH, J=6.0 Hz), 6.92 - 6.85 (m, 3H, 
Ar), 5.13 (s, 1H, OCH2), 4.41 (d, 2H, NCH2, J=6.0 Hz), 3.89 (s, 3H, OCH3), 3.84 (s, 3H, 
OCH3), 3.82 (s, 5H, OCH3 + CH2); δC (100 MHz, CDCl3) 162.25, 159.96, 155.53, 152.81, 
151.10, 134.91, 133.64, 132.84, 131.68, 130.26, 128.34, 128.18, 117.89, 114.23, 114.13, 
112.20, 111.97, 60.70, 56.46, 55.44, 42.56, 28.82.  
(2E)-N-benzyl-3-(3-chloro-4-methoxyphenyl)-2-{[(4-
methoxyphenyl)methoxy]imino}propanamide 31v 
Amide 31v (White solid, 56%) was prepared from OPMB 
acid 32v following the general procedure described earlier.  
Rf 0.23 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.35 – 7.23 (m, 8H, Ar), 7.17 – 7.15 
(m, 1H, Ar), 6.99 (t, 1H, NH, J=6.0 Hz), 6.89 – 6.87 (m, 2H, Ar), 6.80 (m, 1H, Ar), 5.11 (s, 
2H, OCH2), 4.50 (d, 2H, NCH2, J=6.0 Hz), 3.86 – 3.85 (m, 5H, OCH3+CH2), 3.81 (s, 3H, 
OCH3); δC (100 MHz, CDCl3) 162.60, 159.87, 152.14, 138.14, 131.25, 130.18, 129.55, 
128.92, 128.86, 127.82, 127.67, 114.12, 112.15, 77.37, 56.31, 55.44, 43.59, 29.03. 
(2E)-N-benzyl-3-(3-bromophenyl)-2-{[(4-methoxyphenyl)methoxy]imino}propanamide 31vi 
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Amide 31vi (White solid, 59%) was prepared from OPMB acid 
32vi following the general procedure described earlier.  Rf 0.48 
(25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.43 (brs, 1H, 
Ar), 7.36 – 7.21 (m, 9H, Ar), 7.12 – 7.08 (m, 1H, Ar), 6.99 (m, 1H, NH), 6.89 – 6.87 (m, 2H, 
Ar), 5.11 (s, 2H, OCH2), 4.51 (d, 2H, NCH2, J=6.0 Hz), 3.92 (s, 2H, CH2), 3.91 (s, 2H, CH2), 
3.81 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.49, 159.86, 151.71, 138.10, 132.49, 130.16, 
130.01, 129.67, 128.88, 128.61, 128.27, 127.83, 127.69, 122.46, 114.12, 77.41, 55.44, 43.61, 
29.81 (one carbon not seen).  
N-Benzyl-3-(3-bromo-4-methoxy-phenyl)-2-methoxyimino-propionamide 62 
 62 (White solid, 50%) was prepared from methoxy-oxime 
acid 63 following the general procedure described earlier.  
Rf 0.34 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 
7.49 (m, 1H, Ar), 7.35 – 7.23 (m, 6H, Ar), 7.00 (brs, 1H, NH), 6.80 – 6.78 (m, 1H, Ar), 4.50 
(d, 2H, NCH2, J=5.96 Hz), 3.97 (s, 2H, OCH3), 3.85 (s, 5H, OCH3 + CH2); δC (100 MHz, 
CDCl3) 162.52, 154.65, 151.85, 138.10, 134.10, 130.01, 129.61, 128.87, 127.91, 127.69, 
112.02, 111.58, 63.18, 56.39, 43.61, 28.75; HRMS m/z (ESI+) found 391.0658 [M+H]+  
C18H20BrN2O3  requires 391.0652; m.p. 104 - 105˚C; HPLC purity:>98% 
 
General Procedure for OPMB de-protection 
To a stirred solution of OPMB protected amide (1.0 eq.) and anisole (4.0 eq.) in 
CH2Cl2 (0.1 M) at room temperature was added aluminum trichloride (4.0 eq.). After 5 min, 
saturated aqueous NaHCO3 solution was added following by a saturated aqueous solution of 
Rochelles salt and stirred for 10 min. The aqueous phase was extracted 3 times with CH2Cl2 
and the combined organic layers were dried over Na2SO4 and concentrated in vacuo. The 
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residue was purified by flash chromatography (25% EtOAc/Pet. spirits) to yield the 
deprotected amide.  
(2E)-N-benzyl-2-(N-hydroxyimino)-3-phenylpropanamide 11 
11(White solid, 71%) was prepared from amide 31i1 following 
the general procedure described earlier.  Rf 0.09 (25% 
EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.54 (s, 1H, N-OH), 7.40 – 7.26 (m, 6H, Ar), 7.26 
– 7.16 (m, 4H, Ar), 6.95 (brs, 1H, NH), 4.49 (d, 2H, J=5.9 Hz,  NCH2), 4.02 (s, 2H, CH2); δC 
(100 MHz, CDCl3) 162.82, 154.09, 138.00, 136.24, 129.51, 128.87, 128.61, 127.86, 127.71, 
126.63, 43.65, 29.48; HRMS (ESI+) m/z found 269.1277 [M+H]+  C16H17N2O2 requires 
269.1285; m.p. 80 – 82˚C; HPLC purity: >97% 
(2E)-2-(N-hydroxyimino)-3-phenyl-N-(2-
phenylethyl)propanamide 12 
12 (White solid, 69%) was prepared from amide 31i2 
following the general procedure described earlier.  Rf 0.08 (25% EtOAc/Pet. spirits); δH (400 
MHz, CDCl3) 7.44 (m, 1H, N-OH), 7.37 – 7.26 (m, 6H, Ar), 7.25 – 7.09 (m, 4H, Ar), 6.69 
(brs, 1H, NH), 3.98 (s, 2H, CH2), 3.56 (apparent t, 2H, NCH2), 2.82 (t, 2H, J=7.0 Hz, CH2); 
δC (100 MHz, CDCl3) 162.80, 154.17, 138.88, 136.30, 129.47, 128.90, 128.77, 128.60, 
126.66, 126.59, 40.80, 35.79, 29.40; HRMS m/z (ESI+) found 283.1451 [M+H]+  
C17H19N2O2 requires 283.1441; m.p. 97 - 98˚C; HPLC purity: >99% 
(2E)-2-(N-hydroxyimino)-3-phenyl-N-(3-phenylpropyl)propanamide 13 
13 (White solid, 50%) was prepared from amide 31i3 
following the general procedure described earlier.  Rf 0.11 
(25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.57 (s, 1H, N-OH), 7.34 – 7.17 (m, 10H, 
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Ar),  6.67 (brs, 1H, NH), 3.99 (s, 2H, CH2), 3.33 (apparent q, 2H, NCH2), 2.69 – 2.58 (m, 2H, 
CH2), 1.85 (apparent t, 2H, CH2); δC (100 MHz, CDCl3) 162.97, 154.02, 141.41, 136.33, 
129.48, 128.60, 128.57, 128.49, 126.57, 126.13, 39.20, 33.31, 31.20, 29.39; HRMS m/z 




14 (White solid, 71%) was prepared from amide 31i4 
following the general procedure described earlier.  Rf 0.09 
(25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.73 (s, 1H, N-OH), 7.38 (s, 2H, Ar), 7.34 – 
7.20 (m, 5H, Ar), 7.00 (brs, 1H, NH), 4.39 (d, 2H, J=6.2 Hz, NCH2), 4.01 (s, 2H, CH2), 3.86 
(s, 3H, OCH3); δC (100 MHz, CDCl3) 163.02, 153.87, 153.67, 136.83, 136.04, 131.86, 129.44, 
128.70, 126.74, 118.47, 60.77, 42.02, 29.46; HRMS m/z (ESI+) found 456.9575 [M+H]+  
C17H17Br2N2O3 requires 456.9581; m.p. 163 - 164˚C; Crystal data: C17H17Br2N2O3, M = 
465.14, monoclinic, space group P1 21/c 1, a = 13.826(5) Å, b = 19.443(7) Å, c = 
14.832(6) Å, V = 3725 (2) Å3, Z = 8, Dc = 1.659 g/cm3; HPLC purity: >98% 
(2E)-N-[(3-bromo-4-methoxyphenyl)methyl]-2-(N-
hydroxyimino)-3-phenylpropanamide 15 
15 (White solid, 65%) was prepared from amide 31i5 
following the general procedure described earlier.  Rf 0.09 (25% EtOAc/Pet. spirits); δH (400 
MHz, CDCl3) 7.52 (s, 1H, N-OH), 7.44 (m, 1H, Ar), 7.35 (m, 2H, Ar), 7.29 (m, 2H, Ar), 7.19 
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CH2), 3.88 (s, 3H, CH3); δC (100 MHz, CDCl3) 162.98, 155.49, 153.83, 136.20, 132.80, 
131.66, 129.47, 128.63, 128.15, 126.64, 112.16, 111.95, 56.46, 42.53, 29.45; HRMS m/z 
(ESI+) found 377.0481 [M+H]+  C17H18BrN2O3 requires 377.0495; m.p. 103 - 105˚C; HPLC 
purity: >95% 
(2E)-N-benzyl-3-(3-bromo-4-methoxyphenyl)-2-(N-hydroxyimino)propanamide 16 
16 (White solid, 55%) was prepared from amide 31iii1 
following the general procedure described earlier.  Rf 0.12 
(25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.77 (s, 
1H, N-OH), 7.55 (m, 1H, Ar), 7.35 – 7.26 (m, 4H, Ar), 7.26 – 7.19 (m, 2H, Ar), 6.95 (brs, 1H, 
NH), 6.79 (m, 1H, Ar), 4.48 (d, 2H, J=5.9 Hz, NCH2), 3.92 (s, 2H, CH2), 3.85 (s, 3H, OCH3); 
δC (100 MHz, CDCl3) 162.74, 154.78, 153.71, 137.94, 134.22, 129.86, 129.71, 128.90, 
127.85, 127.74, 112.12, 56.42, 43.69, 28.23 (one carbon not seen); HRMS m/z (ESI+) found 
377.0503 [M+H]+  C17H18BrN2O3 requires 377.0495; m.p. 139 -141˚C; HPLC purity: >96% 
(2E)-2-(N-hydroxyimino)-3-(4-methoxyphenyl)-N-(2-phenylethyl)propanamide 17 
17 (White solid, 81%) was prepared from amide 31ii2 following the general procedure 
described earlier.  Rf 0.07 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.66 (d, 1H, , 
J=58.4 Hz, N-OH), 7.33 – 7.18 (m, 5H, Ar), 7.15 (m, 2H, Ar), 6.80 (m, 2H, Ar), 6.69 (brs, 
1H, NH), 3.91 (s, 2H, CH2), 3.77 (s, 3H, OCH3), 3.54 (apparent q, 2H, NCH2), 2.81 (t, 2H, 
J=7.0 Hz, CH2); δC (100 MHz, CDCl3) 162.94, 158.36, 154.33, 138.87, 130.53, 128.89, 
128.75, 128.35, 126.64, 114.02, 55.38, 40.79, 35.78, 28.47; HRMS m/z (ESI+) found 
313.1544 [M+H]+  C18H21N2O3 requires 313.1547; m.p. 96 - 97˚C; HPLC purity: >95% 




18 (White solid, 54%) was prepared from amide 31ii3 
following the general procedure described earlier.  Rf 
0.11 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 8.37 (s, 1H, N-OH), 7.29 – 7.12 (m, 7H, 
Ar), 6.79 (m, 2H, Ar), 6.71 (brs, 1H, NH), 3.93 (s, 2H, CH2), 3.75 (s, 3H, OCH3), 3.31 
(apparent q, 2H, NCH2), 2.61 (t, 2H, J=7.7 Hz, CH2), 1.89 – 1.76 (m, 2H, CH2); δC (100 MHz, 
CDCl3) 163.23, 158.32, 154.08, 141.40, 130.55, 128.59, 128.47, 128.41, 126.12, 114.00, 
55.35, 39.20, 33.29, 31.18, 28.45; HRMS m/z (ESI+) found 327.1691 [M+H]+  C19H23N2O3 




19 (White solid, 54%) was prepared from amide 
31ii4 following the general procedure described earlier.  Rf 0.15 (25% EtOAc/Pet. spirits); δH 
(400 MHz, CDCl3) 7.67 (s, 1H, N-OH), 7.38 (s, 2H, Ar), 7.28 (m, 2H, Ar), 6.99 (brs, 1H, 
NH), 6.85 – 6.78 (m, 2H, Ar), 4.39 (d, 2H,  J=6.2 Hz, NCH2), 3.94 (s, 2H, CH2), 3.86 (s, 3H, 
OCH3), 3.77 (s, 3H, OCH3); δC (100 MHz, CDCl3) 163.06, 158.46, 154.17, 153.65, 136.85, 
131.84, 130.51, 128.05, 118.46, 114.13, 60.77, 55.39, 41.99, 28.54; HRMS m/z (ESI+) found 
486.9687 [M+H]+ C18H19Br2N2O4 requires 486.9687; m.p. 143 - 145˚C; HPLC purity: >95% 
(2E)-N-[(3-bromo-4-methoxyphenyl)methyl]-2-(N-
hydroxyimino)-3-(4-methoxyphenyl)propanamide 20 
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31ii5 following the general procedure described earlier.  Rf 0.12 (25% EtOAc/Pet. spirits); δH 
(400 MHz, CDCl3) 7.71 (s, 1H, N-OH), 7.42 (m, 1H, Ar), 7.28 (m, 2H, Ar), 7.14 (m, 1H, Ar), 
6.91 (brs, 1H, NH), 6.87 – 6.77 (m, 3H, Ar), 4.38 (d, 2H, J=6.0 Hz,  NCH2), 3.94 (s, 2H, 
CH2), 3.87 (s, 3H, CH3), 3.77 (s, 3H, CH3); δC (100 MHz, CDCl3) 162.92, 158.42, 155.50, 
154.25, 132.80, 131.72, 130.55, 128.22, 128.14, 114.08, 112.16, 111.96, 56.46, 55.39, 42.51, 
28.55; HRMS m/z (ESI+) found 407.0603 [M+H]+  C18H19BrN2O4 requires 407.0601; m.p. 
121 - 123˚C; HPLC purity: >95% 
(2E)-N-benzyl-2-(N-hydroxyimino)-3-(4-methoxyphenyl)propanamide 21 
21 (White solid, 61%) was prepared from amide 31ii1 
following the general procedure described earlier.  Rf 0.07 
(25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.52 (s, 1H, N-OH), 7.36 – 7.20 (m, 7H, Ar), 
6.94 (brs, 1H, NH), 6.85 – 6.78 (m, 2H, Ar), 4.48 (d, 2H, J=5.9 Hz, NCH2), 3.95 (s, 2H, CH2), 
3.77 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.87, 158.40, 154.35, 138.01, 130.58, 128.86, 
128.27, 127.85, 127.69, 114.04, 55.39, 43.63, 28.56; HRMS m/z (ESI+) found 321.1211 
[M+H]+  C17H18N2O3 requires 321.1210; m.p. 156 - 
158˚C; HPLC purity: >97% 
 (2E)-3-(3-bromo-4-methoxyphenyl)-2-(N-
hydroxyimino)-N-(2-phenylethyl)propanamide 22  
22 (White solid, 75%) was prepared from amide 31iii2 following the general procedure 
described earlier.  Rf 0.12 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.94 (s, 1H, N-
OH), 7.52 (m, 1H, Ar), 7.29 (m, 2H, Ar), 7.25 – 7.18 (m, 2H, Ar), 7.18 – 7.11 (m, 2H, Ar), 
6.78 (m, 1H, Ar), 6.71 (brs, 1H, NH), 3.89 (s, 2H, CH2), 3.85 (s, 3H, OCH3), 3.55 (dd, 2H, 
J=13.2, 7.0 Hz, CH2), 2.81 (t, 2H, J=7.0 Hz, CH2); δC (100 MHz, CDCl3) 162.80, 154.68, 
153.60, 138.79, 134.16, 129.89, 129.68, 128.87, 128.77, 126.68, 112.03, 111.61, 56.39, 40.82, 
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35.74, 28.13; HRMS m/z (ESI+) found 413.0466 [M+Na]+ C18H19BrN2NaO3 requires 
413.0471; m.p. 100 - 102˚C; HPLC purity: >97% 
(2E)-3-(3-bromo-4-methoxyphenyl)-2-(N-hydroxyimino)-N-(3-phenylpropyl)propanamide 23 
23(White solid, 51%) was prepared from amide 31iii3 
following the general procedure described earlier.  Rf 
0.16 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 
7.68 (s, 1H, N-OH), 7.53 (m, 1H, Ar), 7.36 – 7.22 (m, 3H, Ar), 7.15 (m, 3H, Ar), 6.78 (m, 1H, 
Ar), 6.67 (brs, 1H, NH), 3.86 (m, 5H, CH2, OCH3), 3.41 – 3.22 (m, 2H, CH2), 2.73 – 2.55 (m, 
2H, CH2), 1.85 (apparent quintet, 2H, CH2); δC (100 MHz, CDCl3) 162.67, 141.40, 134.21, 
129.69, 128.62, 128.50, 126.15, 112.03, 77.48, 77.16, 76.84, 56.38, 39.22, 33.35, 31.20, 
28.14 (one carbon not seen); HRMS m/z (ESI+) found 427.0628  [M+Na]+ C18H19BrN2NaO3 




24 (White solid, 42%) was prepared from amide 
31iii4 following the general procedure described earlier.  Rf 0.12 (25% EtOAc/Pet. spirits); 
δH (400 MHz, CDCl3) 7.70 (s, 1H, N-OH), 7.54 (m, 1H, Ar), 7.39 (s, 2H, Ar), 7.28 (m, 1H, 
Ar), 7.00 (brs, 1H, NH), 6.81 (m, 1H, Ar), 4.40 (d, 2H, J=6.2 Hz, NCH2), 3.92 (s, 2H, CH2), 
3.86 (d, 6H, OCH3 + OCH3); δC (100 MHz, CDCl3) 162.81, 154.80, 153.53, 136.75, 134.20, 
131.88, 129.64, 129.58, 118.49, 112.10, 111.70, 77.36, 60.78, 56.40, 42.04, 28.20; HRMS 
m/z (ESI+) found 586.8617 [M+Na]+  C18H17Br3N2O4 requires 586.8611; m.p. 180 - 182˚C; 
















25 (Yellow gum, 66%) was prepared from amide 
31iii5 following the general procedure described 
earlier.  Rf 0.12 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.74 (s, 1H, N-OH), 7.54 (m, 
1H, Ar), 7.43 (m, 1H, Ar), 7.28 (m, 1H,  Ar), 7.16 (m, 1H, Ar), 6.92 (brs, 1H, NH), 6.82 (m, 
2H, Ar), 4.39 (d, 2H, J=6.0 Hz, NCH2), 3.91 (s, 2H, CH2), 3.86 (m, 6H, OCH3+OCH3); δC 
(100 MHz, CDCl3) 162.65, 155.53, 154.87, 153.67, 134.20, 132.82, 131.62, 129.73, 129.69, 
128.16, 112.20, 112.08, 111.65, 77.36, 56.47, 56.40, 42.55, 28.20; HRMS m/z (ESI+) found 
508.9487  [M+Na]+  C18H18Br2N2O4 requires 508.9506; HPLC purity: >96% 
(2E)-N-benzyl-3-(3,5-dibromo-4-methoxyphenyl)-2-(N-hydroxyimino)propanamide 26 
26 (White solid, 54%) was prepared from amide 31iv1 
following the general procedure described earlier.  Rf 0.12 
(25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 8.25 (s, 
1H, N-OH), 7.44 (s, 2H, Ar), 7.29 – 7.14 (m, 5H, Ar), 6.94 (brs, 1H, NH), 4.43 (d, 2H, J=5.9 
Hz, NCH2), 3.84 (s, 2H, CH2), 3.78 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.62, 152.88, 
152.56, 137.73, 134.84, 133.63, 128.93, 127.85, 127.81, 118.01, 60.72, 43.74, 28.15; HRMS 
m/z (ESI+) found 476.9409 [M+Na]+  C17H16Br2N2O3 requires 476.9420; m.p. 139 - 140˚C; 
HPLC purity: >98% 
(2E)-3-(3,5-dibromo-4-methoxyphenyl)-2-(N-
hydroxyimino)-N-(2-phenylethyl)propanamide 27 
27 (White solid, 66%) was prepared from amide 31iv2 
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following the general procedure described earlier.  Rf 0.12 (25% EtOAc/Pet. spirits); δH (400 
MHz, CDCl3) 7.72 (s, 1H, N-OH), 7.48 (s, 2H, Ar), 7.30 (m, 2H, Ar), 7.26 – 7.12 (m, 3H, Ar), 
6.71 (brs, 1H, NH), 3.86 (m, 5H, NCH2 +  OCH3), 3.57 (dd, 2H, J=13.2, 7.0 Hz, CH2), 2.84 (t, 
2H, J=7.0 Hz, CH2); δC (100 MHz, CDCl3) 162.36, 152.88, 152.81, 138.73, 134.85, 133.61, 
128.87, 128.81, 126.74, 118.00, 60.72, 40.84, 35.74, 28.09; HRMS m/z (ESI+) found 
492.9552 [M+Na]+  C18H18Br2N2O3 requires 492.9557; m.p. 137 - 138˚C; HPLC purity: >98% 
 (2E)-3-(3,5-dibromo-4-methoxyphenyl)-2-(N-
hydroxyimino)-N-(3-phenylpropyl)propanamide 28 
28 (White solid, 66%) was prepared from amide 
31iv3 following the general procedure described 
earlier.  Rf 0.11 (20% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.75 (s, 1H, N-OH), 7.49 (s, 
2H, Ar), 7.28 – 7.26 (m, 2H, Ar), 7.23 – 7.10 (m, 3H, Ar), 6.68 (brs, 1H, NH), 3.86 (d, 5H, 
OCH3 + NCH2), 3.35 (apparent q, 2H, CH2), 2.71 – 2.60 (m, 2H, CH2), 1.87 (apparent quintet, 
2H, CH2); δC (100 MHz, CDCl3) 162.39, 152.85, 141.33, 134.87, 133.63, 128.64, 128.50, 
126.18, 118.00, 77.36, 60.71, 39.28, 33.35, 31.15, 28.10; HRMS m/z (ESI+) found 504.9740 




29 (Yellow solid, 69%) was prepared from amide 
31iv4 following the general procedure described earlier.  Rf 0.11 (20% EtOAc/Pet. spirits); 
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NH), 4.41 (d, 2H, J=6.2 Hz, NCH2), 3.90 (s, 2H, CH2), 3.86 (m, 6H, OCH3 + OCH3); δC (100 
MHz, CDCl3) 162.53, 153.77, 152.98, 152.53, 136.60, 134.60, 133.62, 131.95, 118.54, 
118.09, 60.79, 60.73, 42.12, 28.14; HRMS m/z (ESI+) found 662.7708 [M+Na]+  




30 (White solid, 50%) was prepared from amide 
31iv5 following the general procedure described earlier.  Rf 0.11 (20% EtOAc/Pet. spirits); 
δH (400 MHz, CDCl3) 11.24 (s, 1H, N-OH), 7.98 (brs, 1H, NH), 7.57 (s, 2H, Ar), 7.51 (m, 1H, 
Ar), 7.27 (m, 1H, Ar), 7.01 (m, 1H, Ar), 4.48 – 4.34 (m, 2H, NCH2), 3.91 (s, 2H, CH2), 3.84 
(m, 6H, OCH3 + OCH3); δC (100 MHz, CDCl3) 163.76, 155.98, 153.44, 137.17, 134.38, 
134.15, 133.28, 129.00, 118.23, 113.14, 111.77, 60.90, 56.62, 42.47, 42.36 (one carbon not 
seen); HRMS m/z (ESI+) found 564.8787 [M+H]+  C18H17Br3N2O4 requires 564.8791; m.p. 
104 - 105˚C; HPLC purity: >95% 
 (2E)-N-[(4-methoxyphenyl)methyl]-2-(N-hydroxyimino)-3-phenylpropanamide 56 
56 (White solid, 74%) was prepared from amide 31i6 following the general procedure 
described earlier.  Rf 0.13 (25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.92 (s, 1H, N-
OH), 7.35 – 7.344 (m, 2H, Ar), 7.27 – 7.14 (m, 5H, Ar), 6.89 (brs, 1H, NH), 6.84 – 6.82 (m, 
2H, Ar), 4.40 (d, 2H, J=5.8 Hz, NCH2), 4.00 (s, 2H, CH2), 3.78 (s, 3H, CH3); δC (100 MHz, 
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CDCl3) 162.85, 159.22, 153.94, 136.28, 130.05, 129.49, 129.24, 128.58, 126.58, 114.25, 
55.45, 43.14, 29.45; HRMS m/z (ESI+) found 299.1398 [M+H]+  C17H19N2O3 requires 
299.1390; m.p. 113 - 115˚C; HPLC purity: >98% 
(2E)-N-[(3-bromophenyl)methyl]-2-(N-hydroxyimino)-3-phenylpropanamide 57 
57 (White solid, 70%) was prepared from amide 31i7 following 
the general procedure described earlier.  Rf 0.19 (25% 
EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.69 (s, 1H, N-OH), 
7.39 – 7.34 (m, 4H, Ar), 7.29 – 7.26 (m, 2H, Ar), 7.21 – 7.16 (m, 3H, Ar), 6.98 (brs, 1H, NH), 
4.46 (d, 2H, J=6.0 Hz, NCH2), 4.01 (s, 2H, CH2); δC (100 MHz, CDCl3) 162.93, 153.91, 
140.39, 136.13, 130.75, 130.40, 129.47, 128.65, 126.68, 126.38, 122.90, 110.48, 42.97, 29.47; 
HRMS m/z (ESI+) found 347.0402 [M+H]+  C16H16BrN2O2 requires 347.0390; m.p. 153 - 
154˚C; HPLC purity: >98% 
N-Benzyl-3-(3-bromo-phenyl)-2-hydroxyimino-propionamide 58 
58 (White solid, 69%) was prepared from amide 31vi following 
the general procedure described earlier.  Rf 0.12 (25% 
EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 7.98 (s, 1H, N-OH), 7.50 (s, 1H, Ar), 7.34 – 7.24 
(m, 7H, Ar), 7.15 – 7.11 (m, 1H, Ar), 6.97 (brs, 1H, NH), 4.50 (d, 2H, NCH2, J=5.9 Hz), 
3.98 (s, 2H, CH2); δC (100 MHz, CDCl3) 162.68, 153.19, 138.47, 137.78, 132.43, 130.11, 
129.81, 128.90, 128.26, 127.77, 127.86, 122.57, 43.69, 29.08; HRMS m/z (ESI+) found 
347.0399 [M+H]+  C16H16BrN2O2  requires 347.0390; m.p. 127 - 128˚C; HPLC purity: >97% 
3-(3-Bromo-4-methoxy-phenyl)-2-hydroxyimino-N-phenyl-propionamide 59 
59 (White solid, 65%) was prepared from amide 31iii6 
following the general procedure described earlier.  Rf 0.20 
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(25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 8.50 (s, 1H, N-OH), 7.80 (s, 1H, Ar), 7.57 – 
7.54 (m, 3H, Ar), 7.34 – 7.29 (m, 3H, Ar), 7.13 – 7.09 (m, 1H, NH), 6.81 (m, 1H, Ar), 3.96 (s, 
2H, CH2), 3.84 (s, 3H, OCH3); δC (100 MHz, CDCl3) 160.41, 154.78, 153.82, 137.32, 134.24, 
129.72, 129.58, 129.22, 124.67, 119.93, 112.08, 111.67, 56.39, 27.91; HRMS m/z (ESI+) 
found 385.0155 [M+Na]+  C16H15BrN2NaO3 requires 385.0158; m.p. 159 -160˚C; HPLC 
purity:>95% 
3-(3-Bromo-4-methoxy-phenyl)-N-cyclohexyl-2-hydroxyimino-propionamide 60 
60 (White solid, 36%) was prepared from amide 31iii7 
following the general procedure described earlier.  Rf 0.12 
(25% EtOAc/Pet. spirits); δH (400 MHz, CDCl3) 8.31 (s, 1H, 
N-OH), 7.54 (m, 1H, Ar), 7.28 – 7.26 (m, 1H, Ar), 6.78 (m, 1H, Ar), 6.61 (d, 1H, NH, J=8.2 
Hz), 3.88 (s, 2H, CH2), 3.92 (s, 2H, CH2), 3.83 (s, 3H, OCH3), 3.79 – 3.77 (m, 1H, CH), 1.90 
– 1.88 (m, 2H, CH2), 1.74 – 1.58 (m, 3H, CH2+CH), 1.38 – 1.29 (m, 2H, CH2), 1.19 – 1.10 
(m, 3H, CH2+CH); δC (100 MHz, CDCl3) 161.97, 154.62, 153.61, 134.24, 130.05, 129.72, 
112.00, 111.54, 56.37, 48.50, 33.04, 28.12, 25.61, 24.91; HRMS m/z (ESI+) found 369.0813 
[M+H]+  C16H22iirN2O3 requires 369.0808; m.p. 132 -133˚C; Crystal data: C16H21BrN2O3, M 
= 369.26, monoclinic, space group P1 21/c 1, a = 14.3175(9) Å, b = 11.2940(7) Å, c = 
10.3434(6) Å, V = 1657.34(18) Å3, Z = 4, Dc = 1.480 g/cm3; HPLC purity: >99% 
N-Benzyl-3-(3-chloro-4-methoxy-phenyl)-2-hydroxyimino-
propionamide 61 
61 (White solid, 55%) was prepared from amide 31v 
following the general procedure described earlier.  Rf 0.12 (25% EtOAc/Pet. spirits); δH (400 
MHz, CDCl3) 7.77 (s, 1H, N-OH), 7.55 (m, 1H, Ar), 7.35 – 7.26 (m, 4H, Ar), 7.26 – 7.19 (m, 
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CH2), 3.85 (s, 3H, OCH3); δC (100 MHz, CDCl3) 162.74, 154.78, 153.71, 137.94, 134.22, 
129.86, 129.71, 128.90, 127.85, 127.74, 112.12, 56.42, 43.69, 28.23 (one carbon not seen); 
HRMS m/z (ESI+) found 355.0816 [M+Na]+  C17H17ClN2NaO3 requires 355.0820; m.p. 144 -
145˚C; HPLC purity: >95% 
Biology: Materials and Methods 
Amphora coffeaeformis 
 Amphora coffeaeformis (UTEX reference number B2080) was cultured in F/2 
medium in tissue culture flasks in an environmental culture chamber at 24 ˚C with a 12h/12h 
light/dark cycle until confluent. Amphora cells were then removed from the surface of the 
tissue culture flask via gentle scraping and were subsequently broken up by continuous 
pipetting and filtering through a 35 µm nitex mesh. The total number of cells collected per 
milliliter was determined using a hemocytometer and then diluted with 30% salinity filtered 
(0.22 µm filter) seawater to the required concentration prior to use.  
Amphora adhesion assay – single concentration 
 To each wells of a 96-well plate, 2000 Amphora cells suspended in 30% salinity 
seawater were added followed by the addition of 12.5 µg/mL of target compounds with 10 
replicates. The cells were incubated at 24 °C for 24 hours with a 12 hours light, 12 hours dark 
cycle. After 24 hours, any unattached cells were removed by aspirating the medium and 
washing once with distilled water. The number of attached cells remaining was quantified by 
counting one field of view per well under the microscope. The mean values of attached cells 
for each compound were calculated and the results expressed as percentages relative to the 
cell number obtained from the negative control (DMSO). 
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Amphora adhesion assay – dose-response 
 To each wells of a 96-well plate, 2000 Amphora cells suspended in 30% salinity 
seawater were added followed by the addition of the target compounds in a range of 
concentration from 2.5 – 160 µg/mL, with 10 replicates per concentration. The cells were 
incubated at 24 °C for 24 hours with a 12 hours light, 12 hours dark cycle. After 24 hours, 
any unattached cells were removed by aspirating the medium and washing once with distilled 
water. The number of attached cells remaining was quantified by counting one field of view 
per well under the microscope with ultra-violet (UV) light. Under UV light, Amphoras that 
were attached and viable appeared red and were quantified. Amphoras that were not viable 
appeared yellow or green and were assumed to have detached from the surface, thus not 
quantified. The mean values for each concentration was calculated and EC50 values were 
determined by fitting the results from dose-response studies into asymmetric (five parameter) 
curves with GraphPad Prism 5.03 software. 
HEK293T cells and CHIKV 
 Human embryonic kidney HEK293T cell line was obtained from the in-house stocks 
in Singapore Immunology Network (SIgN). The cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 4500 mg/L glucose, 110 mg/L sodium 
pyruvate and 10% fetal bovine serum (FBS). Titrated working stocks with 45,000 pfu/μL of 
full-length CHIKV (La Reunion strain) infectious clone SP6-ICRES1-2SG tagged with 
Gaussia luciferase (CHIKV-Gluc) gene was also obtained from the in-house stocks in SIgN.  
HEK293T cell viability assay  
 Cytotoxicity of candidate compounds was assessed using CellTiter-Glo® luminescent 
cell viability assay (Promega, USA). For the assay, 3 x 104 HEK293T cells were plated per 
well of a 96-well plate and incubated overnight, resulting in monolayer. The cells were 
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treated with synthetic compounds at various concentrations in triplicates, a serial dilution 
series with concentrations of 0.01 μM, 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 
50 μM, 100 μM, 200 μM, 400 μM, 800 μM and 1 mM was used for each screening 
compound. Dilution series was prepared by diluting compound stocks with DMEM (pH 6.8) 
supplemented with 4500 mg/L glucose, 110 mg/L sodium pyruvate and 10% FBS.Cell 
controls received only cells and medium, while blank controls received only medium. After 
exposure for 24 h, cellular levels of ATP were determined as a measure of cell viability. 
Briefly, plates were equilibrated to room temperature for 30 min, 100 μL of CellTiter-Glo® 
reagent was added. After 2 min of shaking and 1 h incubation, the luminometric readout was 
measured using GloMax®-Multi detection system (Promega, USA), and concentrations 
causing 50% cytotoxicity (CC50) were calculated.  
Antiviral assay (CHIKV-Gluc assay)  
 HEK293T cells were seeded into 96-well plates at densities of 3 x 104 cells/well, 
incubated overnight and infected with CHIKV-Gluc Infectious clone (multiplicity of 
infection (MOI) = 0.1) overlay. After the infected cells were incubated for 1.5 h, the virus 
overlay was removed and each screening compound at the same serial dilution range was 
prepared and added in triplicates into the wells. Cell controls received only cells and medium, 
while virus controls received virus but no test compound. At 24 h post-infection, 50 μL 
cultured medium was transferred into a new 96-well plated and 50 μL of coelenterazine H 
working solution (20 μM) was pipetted into the wells. The luminometric readout was 
measured using GloMax®-Multi detection system (Promega, USA), and % infectivity 
(relative to untreated wells) was calculated, and concentrations causing 50% infectivity (EC50) 
were calculated.  
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Data analysis  
 All data from the antiviral and cell viability assays were normalized using untreated 
infections and non-infected cell cultures (in antiviral assays) or untreated and reagent 
background samples (in cell viability assays), which were set as 100% and 0% values, 
respectively. CC50 (in cell viability assays) and EC50 (in antiviral assays) values were 
determined by fitting the results from dose-response studies into asymmetric (five parameter) 
curves with GraphPad Prism 5.03 software. 
Compound libraries and reference compounds  
 All compounds used were synthesized as described, dissolved in dimethyl sulfoxide 
(DMSO) and stored as 100 mM stock solutions. The positive control in the CHIKV assays, 
naringenin was purchased from Sigma-Aldrich, dissolved in DMSO and stored as a 200 mM 
stock solution.  
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Appendix II  
 NMR Spectra 
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HPLC Spectra  
 Compound 11 
Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 
Compound 12 
Solvent: 70% MeOH in H2O 
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Solvent: 50% ACN in H2O 
 
Compound 13 
Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 
  




Solvent: 60% MeOH in H2O 
 
Solvent: 60% ACN in H2O 
 
Compound 15 
Solvent: 70% MeOH in H2O 
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Solvent: 50% ACN in H2O 
 
Compound 16 
Solvent: 70% MeOH in H2O 
 
 
Solvent: 50% ACN in H2O 
 
  




Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 
Compound 18 
Solvent: 70% MeOH in H2O 
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Solvent: 50% ACN in H2O 
 
Compound 19 
Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 
  




Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 
Compound 21 
Solvent: 70% MeOH in H2O 
 
 
Appendix II –Spectra 
173 
 




Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 
  




Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 
Compound 24 
Solvent: 70% MeOH in H2O 
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Solvent: 50% ACN in H2O 
 
Compound 25 
Solvent: 70% MeOH in H2O 
e  
Solvent: 50% ACN in H2O 
 
  




Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 
Compound 27 
Solvent: 70% MeOH in H2O 
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Solvent: 50% ACN in H2O 
 
Compound 28 
Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 
  




Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 
Compound 30 
Solvent: 70% MeOH in H2O 
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Solvent: 50% ACN in H2O 
 
Compound 56 
Solvent: 70% MeOH in H2O 
 
Solvent: 40% ACN in H2O 
 
  




Solvent: 70% MeOH in H2O  
 
Solvent: 60% ACN in H2O 
 
Compound 58 
Solvent: 70% MeOH in H2O  
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Solvent: 50% ACN in H2O  
 
Compound 59 
Solvent: 50 - 90% MeOH in H2O (0.1% Formic acid) 
 
Solvent: 50 - 90% ACN in H2O (0.1% Formic acid) 
 
  




Solvent: 80% MeOH in H2O  
 
Solvent: 65% ACN in H2O  
 
Compound 61 
Solvent: 50 - 90% MeOH in H2O (0.1% Formic acid) 
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Solvent: 50 - 90% ACN in H2O (0.1% Formic acid) 
 
Compound 62 
Solvent: 70% MeOH in H2O 
 
Solvent: 50% ACN in H2O 
 





Table 13. Table of EC50, CC50, S.D. and therapeutic ratio of tested compounds 
Compound EC50 (µM) CC50 (µM) Therapeutic ratio 
11 117.3 ± 3.1 479.6 ± 6.3 4.09 
12 79.9 ± 6.6 354.1 ± 9.5 4,43 
13 55.1 ± 5.3 270.0 ± 5.6 4.90 
14 28.4 ± 1.5 106.8 ± 2.5 3.76 
15 11.5 ± 3.4 130.6 ± 6.2 11.36 
16 13.3 ± 4.2 87.9 ± 7.1 6.61 
17 65.3 ± 2.1 280.0 ± 7.6 4.29 
18 41.8 ± 2.1 222.6 ± 7.7 5.33 
19 35.1 ± 4.5 105.2 ± 4.7 3.00 
20 30.6 ± 3.4 241.8 ± 9.3 7.90 
21 27.5 ± 1.5 >1000 ± 14.7 36.36 
22 25.4 ± 2.1 128.5 ± 3.5 5.06 
23 28.8 ± 1.6 117.3 ± 3.1 4.07 
24 25.2 ± 3.7 67.9 ±  3.6 2.69 
25 23.5 ± 3.1 104.9 ± 6.4 4.46 
26 22.7 ± 5.0 89.7 ± 3.0 3.95 
27 24.2 ± 5.2 60.9 ± 3.4 2.52 
28 25.7 ± 3.7 107.6 ± 3.7 4.19 
29 25.0 ± 2.3 52.8 ± 3.8 2.11 
30 19.6 ± 3.2 55.4 ± 3.8 2.83 
56 69.5 ± 2.4 690 ± 7.1 9.93 
57 25.4 ± 2.5 589.5 ± 8.0 23.21 
58 33.0 ± 2.3 100.0 ± 11.4 3.03 
59 26.0 ± 2.9 80.4 ± 19.9 3.09 
60 53.8 ± 2.2 260.5 ± 7.5 4.84 
61 16.5 ± 1.3 400.0 ± 4.4 24.20 
62 4.3 ± 1.6 >1000 ± 9.5 232.56 
 
  
